[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2617
1. Chen KY, Xiang GA, Wang HN, Xiao FL: [Simultaneous laparoscopic excision for the treatment of rectal carcinoma and the synchronous hepatic metastasis]. Zhonghua Zhong Liu Za Zhi; 2009 Jan;31(1):69-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Simultaneous laparoscopic excision for the treatment of rectal carcinoma and the synchronous hepatic metastasis].
  • OBJECTIVE: To evaluate the therapeutic efficacy of simultaneous laparoscopic excision for the treatment of rectal carcinoma and synchronous hepatic metastasis.
  • METHODS: Totally 38 patients with rectal carcinoma and synchronous hepatic metastasis detected by CT scan were included in this study.
  • Among them, 23 patients in the group A were treated with laparoscopic surgery, and the other 18 patients in the group B with traditional abdominal operation to resect the rectal tumor and hepatic metastasis simultaneously.
  • CONCLUSION: Simultaneous laparoscopic excision of rectal carcinoma and synchronous hepatic metastasis is safe, effective and minimally invasive with a similar survival achieved by traditional open abdominal operation.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy / methods. Liver Neoplasms / surgery. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538876.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Otsuki Y, Shimizu S, Hosoda Y, Nagasawa M, Sato Y, Kobayashi H: Hepatocellular carcinoma with mesothelioma-like dissemination. Pathol Int; 2005 Nov;55(11):738-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No signs of tumor, fibrosis, or cirrhosis were found in the liver, except for a small nodule in the hepatic triangular ligament.
  • The origin of this tumor and its differential diagnosis (malignant mesothelioma, hepatoid adenocarcinoma, and hepatoid yolk sac tumor) are discussed.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Mesothelioma / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Calbindin 2. Carcinoembryonic Antigen / analysis. Carcinoembryonic Antigen / immunology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / analysis. Keratins / immunology. Male. Middle Aged. Mucin-1 / analysis. Mucin-1 / immunology. S100 Calcium Binding Protein G / analysis. S100 Calcium Binding Protein G / immunology. Vimentin / analysis. Vimentin / immunology. alpha-Fetoproteins / analysis. alpha-Fetoproteins / immunology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271087.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / Carcinoembryonic Antigen; 0 / Mucin-1; 0 / S100 Calcium Binding Protein G; 0 / Vimentin; 0 / alpha-Fetoproteins; 68238-35-7 / Keratins
  •  go-up   go-down


3. Park SR, Chun JH, Yu MS, Lee JH, Ryu KW, Choi IJ, Kim CG, Lee JS, Kim YW, Bae JM, Kim HK: Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. Br J Cancer; 2006 May 22;94(10):1402-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):997-1001 [12966415.001]
  • [Cites] J Chemother. 2003 Aug;15(4):400-5 [12962370.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Gan To Kagaku Ryoho. 1994 Jun;21(7):1033-8 [8210254.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):380-3 [7914428.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1773-81 [15550582.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5660-7 [16110025.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):301-6 [10811496.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):47-51 [11249048.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):641-6 [11857295.001]
  • [Cites] Jpn J Clin Oncol. 2002 Jul;32(7):248-54 [12324575.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • (PMID = 16641896.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2361264
  •  go-up   go-down


Advertisement
4. Sakuma M, Fukui S, Nakamura M, Takahashi T, Kitamukai O, Yazu T, Yamada N, Ota M, Kobayashi T, Nakano T, Shirato K: Cancer and pulmonary embolism: thrombotic embolism, tumor embolism, and tumor invasion into a large vein. Circ J; 2006 Jun;70(6):744-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of thrombotic PE was high in those with adenocarcinoma, leukemia and large cell carcinoma, and was low in those with hepatic cell carcinoma.
  • The incidence of PE was high when tumor was present in hematogenous tissue, lungs, ovaries, pancreas and the biliary system, and was low when tumor was present in the liver.
  • The incidence of tumor PE was high with large cell carcinoma, hepatic cell carcinoma and adenocarcinoma, and was also high when tumor was present in the lungs, ovaries, kidneys and liver.

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16723797.001).
  • [ISSN] 1346-9843
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


5. Lotem J, Netanely D, Domany E, Sachs L: Human cancers overexpress genes that are specific to a variety of normal human tissues. Proc Natl Acad Sci U S A; 2005 Dec 20;102(51):18556-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 91 stable clusters obtained, 24 clusters included genes preferentially expressed either only in hematopoietic tissues or in hematopoietic and one to two other tissues; 28 clusters included genes preferentially expressed in various nonhematopoietic tissues such as neuronal, testis, liver, kidney, muscle, lung, pancreas, and placenta.
  • [MeSH-minor] Adenocarcinoma / genetics. Cell Line. Cell Line, Tumor. Health. Humans. Leukemia / classification. Leukemia / genetics. Multigene Family / genetics

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12079-84 [11035779.001]
  • [Cites] J Immunol. 1997 Oct 1;159(7):3555-64 [9317155.001]
  • [Cites] Oncogene. 2001 May 28;20(24):3156-65 [11420732.001]
  • [Cites] Semin Cancer Biol. 2002 Oct;12(5):339-46 [12191633.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):1035-42 [12481426.001]
  • [Cites] Bioinformatics. 2002 Dec;18(12):1585-92 [12490442.001]
  • [Cites] Blood. 2003 Jan 15;101(2):383-9 [12393558.001]
  • [Cites] Leukemia. 2003 Jan;17(1):9-16 [12529654.001]
  • [Cites] Adv Cancer Res. 2003;88:31-52 [12665052.001]
  • [Cites] Front Biosci. 2003 May 1;8:s206-22 [12700034.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]
  • [Cites] Lancet. 2003 Jul 19;362(9379):205-9 [12885482.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16022-7 [15505217.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3679-87 [15226186.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] World J Gastroenterol. 2005 Apr 28;11(16):2390-7 [15832406.001]
  • [Cites] Blood. 2005 May 1;105(9):3488-92 [15650059.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4881-7 [15930309.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Oct;25(10):760-8 [14528097.001]
  • [Cites] Curr Opin Oncol. 2004 May;16(3):211-4 [15069314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7 [15075390.001]
  • [Cites] Semin Hematol. 1981 Jan;18(1):72-7 [7010612.001]
  • [Cites] Leukemia. 1997 Apr;11 Suppl 3:271-2 [9209362.001]
  • [Cites] Oncogene. 2001 May 28;20(24):3139-55 [11420731.001]
  • (PMID = 16339305.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1317977
  •  go-up   go-down


6. Kim HW, Cai QY, Jun HY, Chon KS, Park SH, Byun SJ, Lee MS, Oh JM, Kim HS, Yoon KH: Micro-CT imaging with a hepatocyte-selective contrast agent for detecting liver metastasis in living mice. Acad Radiol; 2008 Oct;15(10):1282-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micro-CT imaging with a hepatocyte-selective contrast agent for detecting liver metastasis in living mice.
  • The detection and monitoring of tumors in the liver in live animals using micro-CT is challenging.
  • We evaluated the feasibility of high-resolution micro-CT enhanced with a hepatocyte-selective contrast agent for detecting liver metastases in a live murine model.
  • MATERIALS AND METHODS: Hepatic metastases were induced in 10 BALB/C mice.
  • Two mice each were randomly selected on days 3, 5, 7, 10, and 13 after CT26 colon adenocarcinoma cells were injected into the portal vein; micro-CT imaging was performed at 10 minutes and 4 hours after intravenous administration of a hepatocyte-selective contrast agent at a dose of 0.4 mL/mouse.
  • The attenuation values of the normal liver and the tumors were obtained.
  • Gross or histopathologic evaluation was performed for correlating the liver tumors with the micro-CT images.
  • The sizes of the individual liver metastases measured by micro-CT and on the excised specimen were highly correlated (P < .001).
  • CONCLUSIONS: High-resolution micro-CT enhanced with a hepatocyte-selective contrast agent can be a promising tool for detecting liver metastases in a live murine model.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / secondary. Contrast Media. Hepatocytes / radiography. Liver Neoplasms / radiography. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790400.001).
  • [ISSN] 1878-4046
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


7. Padda M, Vadgama J, Sandhu P, Dev A, Giannikopoulos I: Clinical significance of incidental colorectal wall thickening on computed tomography scan in African-American and Hispanic patients. Dig Dis Sci; 2007 Nov;52(11):3159-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathological findings revealed colitis in 7 (33%), adenoma in 4 (19%), hyperplastic polyps in 4 (19%), adenocarcinoma in 2 (9%), lymphoid aggregates in 2 (9%), melanosis coli in 1 (5%), and normal in 1 (5%) in the abnormal examination group.
  • [MeSH-minor] Adult. Aged. Colonoscopy. Diagnosis, Differential. Female. Humans. Hypertrophy / radiography. Male. Middle Aged. Predictive Value of Tests. Prevalence. Retrospective Studies. United States / epidemiology


8. Tang ZQ, Han LY, Lin HH, Cui J, Jia J, Low BC, Li BW, Chen YZ: Derivation of stable microarray cancer-differentiating signatures using consensus scoring of multiple random sampling and gene-ranking consistency evaluation. Cancer Res; 2007 Oct 15;67(20):9996-10003
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This method was tested by using a well-studied 62-sample colon cancer data set and two other cancer data sets (86-sample lung adenocarcinoma and 60-sample hepatocellular carcinoma).
  • [MeSH-minor] Biometry / methods. Carcinoma, Hepatocellular / genetics. Humans. Liver Neoplasms / genetics. Lung Neoplasms / genetics. Pattern Recognition, Automated / methods. Reproducibility of Results

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942933.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. de Graaf GW, Ayantunde AA, Parsons SL, Duffy JP, Welch NT: The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol; 2007 Oct;33(8):988-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laparoscopy has become a safe and effective staging tool in upper gastrointestinal cancers because of its ability to detect small peritoneal and liver metastases missed by imaging techniques.
  • RESULTS: Staging laparoscopy changed treatment decision in 84 cases (20.2%): locally advanced disease in 17, extensive lymph node disease in four and distant metastases (liver and peritoneum) in 63 cases.
  • CONCLUSION: Staging laparoscopy avoided unnecessary laparotomy in 20.2% of our patients and was most useful in adenocarcinoma, distal oesophageal, GOJ and gastric cancers and probably not necessary in lesions of the upper two-third of the oesophagus.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Laparoscopy. Neoplasm Staging. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344017.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Peek RM: Prevention of Gastric Cancer: When is Treatment of Helicobacter Pylori Warranted? Therap Adv Gastroenterol; 2008 Jul;1(1):19-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic gastritis induced by Helicobacter pylori (H. pylori) is the strongest known risk factor for adenocarcinoma of the distal stomach, yet the effects of bacterial eradication on carcinogenesis remain unclear. H. pylori isolates possess substantial genotypic diversity, which engenders differential host inflammatory responses that influence clinical outcome. H. pylori strains that possess the cag pathogenicity island and secrete a functional cytotoxin induce more severe gastric injury and further augment the risk for developing distal gastric cancer.
  • It is important to gain insight into the pathogenesis of H. pylori-induced gastritis and adenocarcinoma not only to develop more effective treatments for gastric cancer, but also because it might serve as a paradigm for the role of chronic inflammation in the genesis of other malignancies that arise within the gastrointestinal tract.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1037-42 [15842576.001]
  • [Cites] Chin J Dig Dis. 2005;6(3):114-5 [16045599.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Feb;2(2):90-7; quiz 1 p following 113 [16264881.001]
  • [Cites] Gastroenterology. 2006 Jan;130(1):188-206; quiz 212-3 [16401482.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):2951-4 [16707587.001]
  • [Cites] Methods Mol Biol. 2006;341:185-95 [16799199.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 19;98(14):974-83 [16849680.001]
  • [Cites] World J Gastroenterol. 2006 Sep 21;12(35):5599-605 [17007010.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4617-26 [17237808.001]
  • [Cites] J Gastroenterol. 2007 Jan;42 Suppl 17:7-9 [17238018.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2007;21(2):281-97 [17382277.001]
  • [Cites] Arch Intern Med. 2007 Apr 23;167(8):821-7 [17452546.001]
  • [Cites] Nature. 2007 May 17;447(7142):330-3 [17507984.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):1003-8 [18192401.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):379-87 [18199531.001]
  • [Cites] J Biol Chem. 1995 Jul 28;270(30):17771-7 [7629077.001]
  • [Cites] J Clin Microbiol. 1995 Jan;33(1):28-32 [7699060.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12778-83 [10535999.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14559-64 [10588744.001]
  • [Cites] Gastroenterology. 2000 Jan;118(1):36-47 [10611152.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1263-8 [10655519.001]
  • [Cites] J Exp Med. 2000 Feb 21;191(4):593-602 [10684851.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1497-500 [10688800.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] Gastroenterology. 2000 Jul;119(1):7-14 [10889149.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2206-11 [11007219.001]
  • [Cites] Digestion. 2000;62(2-3):95-9 [11025356.001]
  • [Cites] J Exp Med. 2000 Dec 4;192(11):1601-10 [11104802.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 6;92(23):1881-8 [11106679.001]
  • [Cites] J Clin Invest. 2001 Mar;107(5):611-20 [11238562.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14625-30 [11724955.001]
  • [Cites] Science. 2002 Jan 25;295(5555):683-6 [11743164.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6775-8 [11788577.001]
  • [Cites] Mol Microbiol. 2002 Feb;43(4):971-80 [11929545.001]
  • [Cites] Science. 2002 Jul 26;297(5581):573-8 [12142529.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14428-33 [12391297.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] J Epidemiol. 2003 May;13(3):162-8 [12749604.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1879-90 [12806621.001]
  • [Cites] Science. 2003 Aug 22;301(5636):1099-102 [12934009.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] JAMA. 2004 Jan 14;291(2):187-94 [14722144.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Mar;286(3):G361-6 [14766534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 18;101(20):7727-32 [15128946.001]
  • [Cites] J Hypertens. 2004 Aug;22(8):1475-7 [15257168.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Oct;19(10):1192-8 [15377299.001]
  • [Cites] Cancer Sci. 2004 Nov;95(11):872-7 [15546504.001]
  • [Cites] J Clin Pathol. 1992 Apr;45(4):319-23 [1577969.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):1937-52 [15940628.001]
  • [Cites] Gut. 2005 Nov;54(11):1536-40 [15985559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10646-51 [16027366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16339-44 [16258069.001]
  • [Cites] J Exp Med. 2005 Nov 7;202(9):1235-47 [16275761.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2487-93 [16284368.001]
  • [Cites] J Pathol. 2006 Jan;208(2):233-48 [16362989.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):196-201 [16450397.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] Am J Gastroenterol. 1994 Oct;89(10):1806-10 [7942672.001]
  • [Cites] Lab Invest. 1995 Dec;73(6):760-70 [8558837.001]
  • [Cites] Int J Epidemiol. 1996 Jun;25(3):494-504 [8671549.001]
  • [Cites] Lancet. 1996 Jul 20;348(9021):150-4 [8684154.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jun;5(6):477-81 [8781746.001]
  • [Cites] Gut. 1997 Mar;40(3):297-301 [9135515.001]
  • [Cites] J Gastroenterol. 1997 Jun;32(3):289-94 [9213239.001]
  • [Cites] Dig Dis Sci. 1997 Jul;42(7):1383-7 [9246033.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):639-42 [9264278.001]
  • [Cites] Int J Cancer. 1997 Dec 10;73(6):837-9 [9399662.001]
  • [Cites] Scand J Gastroenterol. 1997 Dec;32(12):1215-21 [9438319.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1998 Jan;10(1):41-6 [9512952.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):50-7 [9649458.001]
  • [Cites] J Clin Pathol. 1998 Mar;51(3):225-8 [9659265.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):642-8 [9721161.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):135-9 [9754640.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13317-23 [16543227.001]
  • [Cites] Lancet. 1991 Aug 10;338(8763):332-5 [1677696.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):60-9 [17200707.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):915-8 [17287725.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):905-12 [17324405.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1309-19 [17408661.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4709-15 [17510398.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):659-72 [17681184.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):926-36 [17854597.001]
  • [Cites] Nature. 2007 Oct 18;449(7164):843-9 [17943121.001]
  • [Cites] Cell Host Microbe. 2007 Oct 11;2(4):250-63 [18005743.001]
  • [Cites] Lab Invest. 2008 Mar;88(3):328-36 [18180700.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):945-52 [18395075.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1132-6 [1891021.001]
  • [Cites] N Engl J Med. 1991 Apr 11;324(15):1043-8 [2005942.001]
  • [Cites] Gastroenterology. 1991 Jul;101(1):167-74 [2044906.001]
  • [Cites] BMJ. 1991 Jun 1;302(6788):1302-5 [2059685.001]
  • [Cites] Infect Immun. 1990 Mar;58(3):603-10 [2307514.001]
  • [Cites] Cancer Res. 1990 Aug 1;50(15):4737-40 [2369748.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1777-80 [7473834.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2789-93 [7773928.001]
  • [Cites] Gut. 1993 Oct;34(10):1339-43 [8244098.001]
  • [Cites] Gastroenterology. 1993 Oct;105(4):1098-103 [8405854.001]
  • [Cites] Scand J Gastroenterol. 1996 Jul;31(7):643-7 [8819211.001]
  • [Cites] Dig Dis Sci. 1997 Aug;42(8):1652-9 [9286230.001]
  • [Cites] Science. 1998 Jan 16;279(5349):373-7 [9430586.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4255-9 [9766647.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):298-300 [9766561.001]
  • [Cites] Gastroenterol Clin North Am. 2000 Sep;29(3):579-92, v-vi [11030074.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6376-80 [11103800.001]
  • [Cites] Cell Microbiol. 2000 Apr;2(2):155-64 [11207572.001]
  • [Cites] Gut. 2001 Sep;49(3):347-53 [11511555.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):28-37 [11902583.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 20;94(22):1680-7 [12441323.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):942-50 [12615707.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Science. 2003 May 30;300(5624):1430-4 [12775840.001]
  • [Cites] Cancer Sci. 2003 Mar;94(3):235-9 [12824915.001]
  • [Cites] Curr Opin Infect Dis. 2003 Oct;16(5):445-51 [14501997.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):4-10 [14744726.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):435-42 [15095311.001]
  • [Cites] Gut. 2004 Sep;53(9):1217-9 [15306570.001]
  • [Cites] Curr Opin Gastroenterol. 2004 Jan;20(1):10-5 [15703614.001]
  • [Cites] J Pediatr. 2005 Mar;146(3 Suppl):S21-6 [15758899.001]
  • (PMID = 20953278.001).
  • [ISSN] 1756-283X
  • [Journal-full-title] Therapeutic advances in gastroenterology
  • [ISO-abbreviation] Therap Adv Gastroenterol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077955; United States / NIDDK NIH HHS / DK / R01 DK058587-01A1; United States / NIDDK NIH HHS / DK / R01 DK073902-02; United States / NCI NIH HHS / CA / R01 CA077955-06; United States / NIDDK NIH HHS / DK / DK073902-02; United States / NIDDK NIH HHS / DK / R01 DK073902; United States / NIDDK NIH HHS / DK / R01 DK058587
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; H. pylori / antibiotics / gastric cancer
  •  go-up   go-down


11. Meng LH, Shankavaram U, Chen C, Agama K, Fu HQ, Gonzalez FJ, Weinstein J, Pommier Y: Activation of aminoflavone (NSC 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone gamma-H2AX. Cancer Res; 2006 Oct 1;66(19):9656-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Arylsulfotransferase / physiology. Cross-Linking Reagents / pharmacokinetics. Flavonoids / pharmacokinetics. Histones / biosynthesis. Neoplasm Proteins / biosynthesis. Prodrugs / pharmacokinetics
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Aryl Hydrocarbon Hydroxylases. Biotransformation. Breast Neoplasms / enzymology. Breast Neoplasms / pathology. Cell Line, Tumor / drug effects. Cell Line, Tumor / enzymology. Cytochrome P-450 CYP1A1 / biosynthesis. Cytochrome P-450 CYP1A1 / genetics. Cytochrome P-450 CYP1B1. Cytochrome P-450 Enzyme System / biosynthesis. Cytochrome P-450 Enzyme System / genetics. DNA Adducts. DNA, Neoplasm / drug effects. Drug Resistance, Neoplasm. Feedback, Physiological. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Microsomes, Liver / enzymology. Neoplasms / enzymology. Neoplasms / pathology. RNA, Small Interfering / pharmacology. Receptors, Aryl Hydrocarbon / physiology. Recombinant Fusion Proteins / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018623.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 0 / DNA Adducts; 0 / DNA, Neoplasm; 0 / Flavonoids; 0 / H2AFX protein, human; 0 / Histones; 0 / Neoplasm Proteins; 0 / Prodrugs; 0 / RNA, Small Interfering; 0 / Receptors, Aryl Hydrocarbon; 0 / Recombinant Fusion Proteins; 0 / aminoflavone; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP1B1 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP1B1; EC 2.8.2.1 / Arylsulfotransferase; EC 2.8.2.1 / SULT1A1 protein, human
  •  go-up   go-down


12. Hiraoka A, Yamashita Y, Uesugi K, Koizumi Y, Yamamoto Y, Doi H, Hasebe A, Ichikawa S, Yano M, Miyamoto Y, Ninomiya T, Matsuura B, Horiike N, Michitaka K, Hiasa Y, Nishikage S, Onji M: Three cases of liver abscesses complicated with colon cancer without liver metastasis: importance of screening for digestive disease. Intern Med; 2007;46(24):2013-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of liver abscesses complicated with colon cancer without liver metastasis: importance of screening for digestive disease.
  • We treated 3 patients complicated with colon cancer without liver metastasis, who were admitted to our hospital because of a high fever and diagnosed with liver abscesses.
  • Hepatobiliary diseases were the most common etiology of hepatic abscesses in our hospital in the past 41 cases from 1990 to 2005, 3 of which were due to colon cancer.
  • If a cause is not determined, general screening, especially of the colon tract, should be performed in hepatic abscesses patients.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Colonic Neoplasms / complications. Colonic Neoplasms / diagnosis. Liver Abscess / etiology

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Liver Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084126.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Yoon SM, Myung SJ, Ye BD, Kim IW, Lee NG, Ryu YM, Park K, Kim K, Kwon IC, Park YS, Park CS, Moon DH, Kim DH, Do MY, Byeon JS, Yang SK, Kim JH: Near-infrared fluorescence imaging using a protease-specific probe for the detection of colon tumors. Gut Liver; 2010 12;4(4):488-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NIRF signal intensities were strongly correlated with each tumor stage from adenoma to adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IARC Sci Publ. 2002;(155):1-781 [12812229.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):162-9 [16081511.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):054003 [16292963.001]
  • [Cites] Eur J Cancer. 2006 Dec;42(18):3246-52 [16973348.001]
  • [Cites] Radiology. 2007 Jul;244(1):232-8 [17507718.001]
  • [Cites] Pathol Oncol Res. 2008 Mar;14(1):31-7 [18347934.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1876-82 [16551873.001]
  • [Cites] Lancet Oncol. 2005 Nov;6(11):871-6 [16257795.001]
  • [Cites] Chem Commun (Camb). 2008 Sep 28;(36):4250-60 [18802536.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3355-8, discussion 3358-9 [16585152.001]
  • [Cites] Science. 2006 May 26;312(5777):1168-71 [16728630.001]
  • [Cites] J Exp Med. 2007 Nov 26;204(12):3037-47 [18025128.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [Cites] Nat Biotechnol. 1999 Apr;17(4):375-8 [10207887.001]
  • [Cites] Can J Gastroenterol. 1999 Jun;13(5):423-9 [10377475.001]
  • [Cites] Clin Chim Acta. 2000 Feb 15;291(2):113-35 [10675719.001]
  • [Cites] Int J Oncol. 2000 May;16(5):927-34 [10762628.001]
  • [Cites] Lancet. 2000 Apr 8;355(9211):1211-4 [10770302.001]
  • [Cites] Nat Med. 2001 Jun;7(6):743-8 [11385514.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Gut. 2002 Oct;51 Suppl 5:V10-2 [12221032.001]
  • [Cites] Nat Med. 2003 Jan;9(1):123-8 [12514725.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Cancer Sci. 2003 Nov;94(11):965-73 [14611673.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):568-77 [15189095.001]
  • [Cites] Endoscopy. 2004 Dec;36(12):1094-8 [15578301.001]
  • [Cites] Endoscopy. 2004 Dec;36(12):1109-14 [15578305.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Invest. 1988;6(2):219-31 [3288298.001]
  • [Cites] Mol Carcinog. 1994 Aug;10(4):199-206 [8068180.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3133-40 [8955659.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Lancet. 1990 Aug 11;336(8711):357-9 [1975343.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):406-14 [11832455.001]
  • [Cites] Clin Colorectal Cancer. 2002 Feb;1(4):208-19 [12450419.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):145-50 [12469197.001]
  • (PMID = 21253297.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3021604
  • [Keywords] NOTNLM ; Colon cancer (major topic) / Inflammatory bowel disease (major topic) / Matrix metalloproteinases (major topic) / Near-infrared fluorescence (major topic)
  •  go-up   go-down


14. Wang CC, Tsai MF, Dai TH, Hong TM, Chan WK, Chen JJ, Yang PC: Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1. Cancer Res; 2007 May 15;67(10):4816-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Base Sequence. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Cell Line, Tumor. Enhancer Elements, Genetic. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Molecular Sequence Data. Promoter Regions, Genetic. Proto-Oncogene Proteins c-fos / biosynthesis. Proto-Oncogene Proteins c-fos / genetics. Proto-Oncogene Proteins c-jun / biosynthesis. Proto-Oncogene Proteins c-jun / genetics. Transcriptional Activation. Transfection. Up-Regulation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17510411.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNAJB4 protein, human; 0 / HSP40 Heat-Shock Proteins; 0 / Proto-Oncogene Proteins c-fos; 0 / Proto-Oncogene Proteins c-jun; 0 / Transcription Factor AP-1; 0 / YY1 Transcription Factor; 0 / YY1 protein, human; 0 / fos-related antigen 1
  •  go-up   go-down


15. Schoppmeyer K, Frühauf N, Oldhafer K, Seeber S, Kasimir-Bauer S: Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases. Oncol Rep; 2006 Feb;15(2):449-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases.
  • Patients undergoing resection of hepatic metastases of colorectal cancer have a high risk of extrahepatic recurrence, most likely caused by early tumor cell dissemination or the manipulation of liver tumors during surgical resection.
  • Using immunocytochemistry, we studied 47 patients for cytokeratin (CK)-positive (+) cells in: a) bone marrow (BM) samples to determine whether tumor cell dissemination had already occurred before surgery; and b) blood samples directly taken from the hepatic vein before and during surgery of liver metastases.
  • In addition, normal and malignant liver tissues were evaluated for markers known to be involved in tumor progression and metastasis [urokinase plasminogen activator (uPA), Her-2/neu, epidermal growth factor receptor (EGF-R)] using sandwich enzyme immunoassays.
  • Tumor tissue was obtained from 32/47 patients and normal liver tissue from 24/32 patients.
  • While no differences were found for EGF-R and Her-2/neu, a 9-fold higher expression of uPA could be demonstrated in tumor tissue of 20/32 patients (63%) compared to normal liver tissue.
  • Although uPa is overexpressed in liver metastases of colorectal cancer, and dissemination of CK+ cells during surgery of these metastases is a frequent event in colon cancer, these findings do not predict extrahepatic recurrence.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Digestive System Surgical Procedures / adverse effects. Liver Neoplasms / secondary. Neoplasm Recurrence, Local / etiology. Neoplasm Seeding


16. Molenaar JP, Baten A, Blokx WA, Hoogendam A: Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate. Eur Urol; 2009 Nov;56(5):874-7; quiz 876
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
  • We present the case of an 81-yr-old man with a prostatic adenocarcinoma and a metastatic carcinoid.
  • Simultaneous occurrence of hormonally treated adenocarcinoma of the prostate and a carcinoid has been described before.
  • The pathogenesis of this coincidence is largely unclear; however, androgen deprivation therapy might play a key role in neuroendocrine differentiation of adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Tumor / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary. Nitriles / therapeutic use. Prostatic Neoplasms / drug therapy. Tosyl Compounds / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Biopsy. Humans. Male. Malignant Carcinoid Syndrome / drug therapy. Positron-Emission Tomography. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19171417.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; 51110-01-1 / Somatostatin; A0Z3NAU9DP / bicalutamide
  •  go-up   go-down


17. Sarbia M, Fritze F, Geddert H, von Weyhern C, Rosenberg R, Gellert K: Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: is analysis of cytokeratin 17 expression helpful? Am J Clin Pathol; 2007 Aug;128(2):255-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic adenocarcinoma of unknown primary site, eg, to lymph nodes, liver, or lung, may originate from many organs.
  • A high prevalence of cytokeratin (CK)17 expression in pancreaticobiliary adenocarcinoma was reported, and preliminary data indicate infrequent or missing expression in gastric adenocarcinoma.
  • CK17 expression was as follows: pancreatic, 88%; bile duct, 59%; esophageal, 30%; distal gastric, 28%; gastric cardiac, 27%; and colorectal adenocarcinoma, 6%.
  • These differences were statistically significant for all tumor types except in comparisons of esophageal, cardiac, and distal gastric adenocarcinoma.
  • However, in individual cases of adenocarcinoma of unknown primary site, CK17 results alone are insufficient to differentiate the analyzed tumor entities.
  • [MeSH-major] Adenocarcinoma / chemistry. Bile Duct Neoplasms / chemistry. Gastrointestinal Neoplasms / chemistry. Keratin-17 / analysis. Pancreatic Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638659.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-17
  •  go-up   go-down


18. Iwaya K, Oikawa K, Semba S, Tsuchiya B, Mukai Y, Otsubo T, Nagao T, Izumi M, Kuroda M, Domoto H, Mukai K: Correlation between liver metastasis of the colocalization of actin-related protein 2 and 3 complex and WAVE2 in colorectal carcinoma. Cancer Sci; 2007 Jul;98(7):992-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between liver metastasis of the colocalization of actin-related protein 2 and 3 complex and WAVE2 in colorectal carcinoma.
  • In order to determine whether the same mechanism correlates with liver metastasis from colorectal cancer, paired mirror sections of 154 cancer specimens (29 cases with liver metastasis and 125 cases without liver metastasis in which T factor, gender, primary tumor site, and age at operation were matched) were examined immunohistochemically for the localization of Arp2 and WAVE2.
  • Univariate analysis showed that the colocalization was significantly predictive of liver metastasis (risk ratio [RR] 8.760.
  • High mRNA levels of Arp2, that in situ hybridization revealed to be expressed by the cancer cells, were significantly associated with liver metastasis.
  • These results indicate that the colocalization of Arp2 and WAVE2 is an independent risk factor for liver metastasis of colorectal carcinoma.
  • [MeSH-major] Actin-Related Protein 2 / physiology. Actin-Related Protein 3 / physiology. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Wiskott-Aldrich Syndrome Protein Family / physiology
  • [MeSH-minor] Actins / physiology. Adenocarcinoma / blood supply. Adenocarcinoma / pathology. DNA Primers. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Neoplasm Invasiveness. Polymerase Chain Reaction. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459058.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actin-Related Protein 2; 0 / Actin-Related Protein 3; 0 / Actins; 0 / DNA Primers; 0 / RNA, Messenger; 0 / WASF2 protein, human; 0 / Wiskott-Aldrich Syndrome Protein Family
  •  go-up   go-down


19. Schima W, Ba-Ssalamah A, Goetzinger P, Scharitzer M, Koelblinger C: State-of-the-art magnetic resonance imaging of pancreatic cancer. Top Magn Reson Imaging; 2007 Dec;18(6):421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For adenocarcinoma, which is the most common malignant pancreatic tumor, helical CT has been most often used for detection and staging, but it has limitations in the detection of small cancers 2 cm in diameter or less (sensitivity, 63%).
  • Moreover, it is not very accurate in determining nonresectability, because small liver metastases, peritoneal carcinomatosis, and subtle signs of vascular infiltration may be missed.
  • Neuroendocrine carcinoma may present with a spectrum of appearances at MRI, but the primary tumor and liver metastases are hypervascular in approximately 70%.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Contrast Media. Humans. Neoplasm Metastasis / diagnosis. Neoplasm Staging. Risk Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303400.001).
  • [ISSN] 0899-3459
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 43
  •  go-up   go-down


20. Pekmezci S, Saribeyoglu K, Aytac E, Arvas M, Demirkiran F, Ozguroglu M: Surgery for isolated liver metastasis of ovarian cancer. Asian J Surg; 2010 Apr;33(2):83-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for isolated liver metastasis of ovarian cancer.
  • BACKGROUND: Few studies have been published on liver resection alone or in combination with cytoreductive surgery for liver metastases of ovarian carcinoma.
  • METHODS: Eight patients who underwent liver resection for metastasis of ovarian cancer were included in the study.
  • Total abdominal hysterectomy and bilateral salpingo-oophorectomy had been performed before liver surgery in all patients.
  • The demographic data, follow-up details before and after liver resection, histopathology of the primary ovarian cancer, type of surgery and outcome were evaluated.
  • The mean disease-free interval was 5.38 years from the time of initial surgery to surgery for metastatic liver lesions, and 39 months after liver resection to secondary metastases.
  • Four patients did not have any evidence of disease after liver surgery.
  • CONCLUSION: Indications for liver resection should be considered in selected patients who have a limited extent of metastatic disease from ovarian carcinoma.
  • Liver resection for metastases of ovarian carcinoma could be an effective and feasible approach.

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Asian Surgical Association. Published by Elsevier B.V. All rights reserved.
  • (PMID = 21029944.001).
  • [ISSN] 0219-3108
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Akatsu T, Kameyama K, Kawachi S, Tanabe M, Aiura K, Wakabayashi G, Ueda M, Shimazu M, Kitajima M: Gallbladder carcinoma with osteoclast-like giant cells. J Gastroenterol; 2006 Jan;41(1):83-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 72-year-old woman presented with postprandial abdominal pain and was found to have a mass in the body of the gallbladder with direct liver invasion.
  • Further studies are required to clearly define the prognostic significance of these giant cells in gallbladder cancer and the differences between adenosquamous carcinoma with OGCs and other gallbladder carcinomas (such as adenocarcinoma and squamous cell carcinoma) with those cells.
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):453-9 [7726143.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7260-4 [2169622.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):450-6 [12828610.001]
  • [Cites] Breast. 2001 Jun;10(3):231-6 [14965590.001]
  • [Cites] Endocrinology. 1989 Jul;125(1):20-7 [2544401.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1678-81 [10364044.001]
  • [Cites] Cancer. 1988 May 1;61(9):1872-9 [2451557.001]
  • [Cites] Arch Pathol Lab Med. 1981 Jun;105(6):287-93 [6263212.001]
  • [Cites] Hum Pathol. 1992 Jun;23(6):703-6 [1592394.001]
  • [Cites] Pathol Res Pract. 1993 Mar;189(2):228-31; discussion 232-4 [8321752.001]
  • [Cites] Am J Gastroenterol. 1995 Jul;90(7):1177-9 [7611227.001]
  • (PMID = 16501862.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, Yanaga K: Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg; 2007;14(6):539-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
  • BACKGROUND PURPOSE: Although carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) are the most studied serum tumor markers that have been evaluated for diagnosis and prognosis in patients with pancreatic cancer, little is known of the value of these markers for the prediction of curability and resectability.
  • The remaining 85 failed resection because of unexpected metastasis or locally advanced disease (LD), which was unresectable compared with levels in those patients without liver metastasis or LD.
  • CEA levels were significantly higher in patients with liver metastasis and LD, while CA 19-9 levels were correlated with liver and peritoneal metastases.
  • [MeSH-major] Adenocarcinoma / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Pancreatic Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18040617.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


23. Ishigami S, Hamada T, Nakajo A, Uenosono Y, Arigami T, Setoyama T, Uchikado Y, Matsumoto M, Natsugoe S, Aikou T: [A case of advanced gastric cancer with multiple liver metastases completely responding to combination of paclitaxel and S-1]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1197-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with multiple liver metastases completely responding to combination of paclitaxel and S-1].
  • Pathological diagnosis of the biopsy specimen was moderately-differentiated adenocarcinoma.
  • Abdominal CT suggested multiple liver metastases, so a combination of biweekly paclitaxel(PTX)and S-1 was started.
  • After five courses of this regimen, the liver metastases and primary tumor were remarkably regressed.
  • Nevertheless S-1 monotherapy for liver metastases resulted in a complete response.
  • The combination of PTX and S-1 may be an effective regimen for gastric cancer with liver metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Oxonic Acid / therapeutic use. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Female. Gastroscopy. Humans. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633262.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


24. Sun Z, Hu ZL, Ning XH, Zhou JF, Shao YJ, Duan JH, Yang XD, Bai CM: [Inhibitory effect of low molecular weight heparin on the secretion of vascular endothelial growth factor by tumor cells in vitro]. Zhonghua Zhong Liu Za Zhi; 2009 Nov;31(11):826-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Human lung cancer cell line A549, human liver cancer cell line HepG2, human colon carcinoma cell lines HCT116 and HCT8 were used in this study.
  • RESULTS: The VEGF levels in the control, LMWH, and heparin groups of the pulmonary adenocarcinoma cell line A549 were (1045.89 +/- 165.30) pg/ml, (782.45 +/- 67.17) pg/ml and (916.54 +/- 71.25) pg/ml, respectively.
  • The VEGF levels in the control, LMWH, and heparin groups of the colon adenocarcinoma cell line HCT116 were (955.76 +/- 51.14) pg/ml, (822.89 +/- 142.39) pg/ml and (951.77 +/- 188.22) pg/ml, respectively.
  • The VEGF levels in the control, LMWH, and heparin groups in the colon adenocarcinoma cell line HCT8 were (1290.62 +/- 41.23) pg/ml, (1063.34 +/- 63.82) pg/ml and (1257.14 +/- 11.40) pg/ml, respectively.
  • The VEGF levels in the control, LMWH, and heparin groups in the liver cancer cell line HepG2 were (1083.00 +/- 134.35) pg/ml, (758.00 +/- 84.85) pg/ml and (874.00 +/- 22.62) pg/ml, respectively.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Cycle / drug effects. Cells, Cultured. Culture Media, Conditioned. HCT116 Cells. Hep G2 Cells. Heparin / pharmacology. Humans. RNA, Messenger / metabolism. Tumor Necrosis Factor-alpha / metabolism. Umbilical Veins / cytology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137346.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Heparin, Low-Molecular-Weight; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 9005-49-6 / Heparin
  •  go-up   go-down


25. Ota T, Yoshida M, Kimura M, Kinoshita K: Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer; 2005 Jul-Aug;15(4):657-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a primary treatment, 12 cases chose hormonal treatment with medroxyprogesterone acetate (MPA; 600 mg/day) due to no findings of myometrial invasion and diagnosis of a grade 1, well-differentiated adenocarcinoma.
  • One of the eight patients died of the metastasized disease to the liver and brain after hysterectomy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Medroxyprogesterone Acetate / therapeutic use
  • [MeSH-minor] Adult. Age of Onset. Combined Modality Therapy. Fatal Outcome. Female. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Receptors, Progesterone / analysis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16014120.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Progesterone; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


26. Arai O, Kakutani A, Mouri H, Ikeda H, Notohara K, Matsueda K: [A case of advanced gastric cancer growing extramurally with gynecomastia and high hCG-beta serum level]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1369-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was a 51-year-old man admitted for a gastric tumor growing extramurally and multiple liver tumors revealed by computed tomography, with chief complaints of abdominal and breast mass.
  • Upper gastrointestinal endoscopy showed gastric cancer of Borrmann type 2 and biopsy specimens showed poorly-differentiated adenocarcinoma.
  • Pathological examination from liver tumor showed the tumor cells greatly resembled gastric tumor and were immunohistochemically positive for hCG-beta.
  • He received chemotherapy, but died of hepatic failure about 8 months after initial diagnosis.
  • When we see a patient with gynecomastia and the high serum hCG-beta levels, it is important that hCG-beta producing-gastric cancer should be considered as a possible malignant tumor of the stomach.
  • [MeSH-minor] Biopsy. Fatal Outcome. Humans. Liver Neoplasms / pathology. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647729.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


27. Gulati MS, Sabharwal T, Dourado R, Adam A: Percutaneous biliary internal decompression in a patient with simultaneous malignant biliary and duodenal obstruction and surgically modified anatomy. Australas Radiol; 2007 Dec;51 Suppl:B334-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous biliary internal decompression in a patient with simultaneous malignant biliary and duodenal obstruction and surgically modified anatomy.
  • In the case report we present here, the patient had had duodenal and biliary obstruction secondary to hepatic flexure adenocarcinoma and presented with recurrent obstructive jaundice.
  • [MeSH-major] Adenocarcinoma / surgery. Bile Duct Neoplasms / surgery. Decompression, Surgical / methods. Duodenal Obstruction / surgery. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991100.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


28. Wright JL, Lin DW, Dewan P, Montgomery RB: Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. Int J Urol; 2005 Nov;12(11):1012-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of TLS in a patient with metastatic adenocarcinoma of the prostate after treatment with paclitaxel chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents, Phytogenic / adverse effects. Paclitaxel / adverse effects. Prostatic Neoplasms / therapy. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Bone Marrow Neoplasms / drug therapy. Bone Marrow Neoplasms / secondary. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Hematuria / etiology. Humans. Hydronephrosis / etiology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Prostate-Specific Antigen / blood. Renal Dialysis. Renal Insufficiency / etiology. Renal Insufficiency / therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351664.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; EC 3.4.21.77 / Prostate-Specific Antigen; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


29. Rossi H, Rothenberger DA: Surgical treatment of colon cancer. Surg Oncol Clin N Am; 2006 Jan;15(1):109-27, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Liver Neoplasms / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Laparoscopy. Male. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16389153.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 109
  •  go-up   go-down


30. Kato K, Sugimoto H, Kanazumi N, Nomoto S, Takeda S, Nakao A: Intra-operative application of real-time tissue elastography for the diagnosis of liver tumours. Liver Int; 2008 Nov;28(9):1264-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-operative application of real-time tissue elastography for the diagnosis of liver tumours.
  • The aim of this study was to evaluate the usefulness of RTE for the differential diagnosis of liver tumours during surgical exploration.
  • METHODS: Fifty-five liver tumours in 44 patients were examined with RTE, concomitant with routine intra-operative ultrasonography.
  • Elasticity images were classified into four types, from type A (even strain) to type D (no strain), according to the distribution and the degree of the strain contrasted with that of the surrounding liver [elasticity type of liver tumour (ETLT)].
  • We evaluated the consistency of the findings of RTE with the pathological diagnosis as a reference standard.
  • RESULTS: All malignant lesions showed various degrees of strain reduction in the tumour tissue.
  • CONCLUSION: Application of RTE in surgical exploration provided significant information about the elasticity of liver tumours.
  • RTE, using a new criterion, ETLT, enabled us to distinguish rather accurately between two common malignancies: HCC and metastatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Elasticity Imaging Techniques. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Care. Liver / pathology. Liver / surgery. Liver / ultrasonography. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331239.001).
  • [ISSN] 1478-3231
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Boonstra JJ, van Marion R, Beer DG, Lin L, Chaves P, Ribeiro C, Pereira AD, Roque L, Darnton SJ, Altorki NK, Schrump DS, Klimstra DS, Tang LH, Eshleman JR, Alvarez H, Shimada Y, van Dekken H, Tilanus HW, Dinjens WN: Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst; 2010 Feb 24;102(4):271-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
  • In a worldwide effort, we verified the authenticity of all available esophageal adenocarcinoma (EAC) cell lines.
  • [MeSH-major] Adenocarcinoma. Cell Line, Tumor. Clinical Trials as Topic / standards. DNA Fingerprinting. Esophageal Neoplasms. Tandem Repeat Sequences

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):233-6 [11252900.001]
  • [Cites] Virchows Arch. 2001 May;438(5):451-6 [11407472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8012-7 [11416159.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 31;286(4):792-801 [11520067.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):299-307 [11832445.001]
  • [Cites] Am J Gastroenterol. 2004 Feb;99(2):218-24 [15046208.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1337-46 [15131795.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Surgery. 2004 Aug;136(2):160-8 [15300175.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G743-8 [15231484.001]
  • [Cites] Science. 1980 Aug 8;209(4457):719-20 [7394535.001]
  • [Cites] Science. 1981 Apr 24;212(4493):446-52 [6451928.001]
  • [Cites] Science. 1989 Jul 21;245(4915):301-5 [2787530.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):649-57 [8334620.001]
  • [Cites] Br J Cancer. 1997;75(2):258-63 [9010035.001]
  • [Cites] J Surg Res. 2005 Jul 1;127(1):53-8 [15964304.001]
  • [Cites] Mol Cancer. 2005;4:24 [16022731.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7996-8001 [17804709.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4971-80 [18676772.001]
  • [Cites] Dis Esophagus. 2008;21(6):514-21 [18840136.001]
  • [Cites] Dig Dis Sci. 2008 Dec;53(12):3055-64 [18512153.001]
  • [Cites] Cancer Biol Ther. 2008 Nov;7(11):1753-5 [18787394.001]
  • [CommentIn] J Natl Cancer Inst. 2010 Feb 24;102(4):212-3 [20075369.001]
  • (PMID = 20075370.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA071606; United States / NCI NIH HHS / CA / R01 CA071606-12; United States / NCI NIH HHS / CA / R01 CA154365
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / GRN163L peptide; 0 / Oligonucleotides; 0 / Oligopeptides; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC2902814
  •  go-up   go-down


32. Adhikari RC, Tuladhar A, Shrestha S, Sharma SK: Deep-seated thoracic and abdominal lesions: usefulness of ultrasound guided fine needle aspiration cytology, a 3 year experience. Nepal Med Coll J; 2010 Mar;12(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These included liver (125 cases), lung (81 cases), abdominal and mediastinal lymph nodes (29 cases), ovary (14 cases), omentum (12 cases), pancreas (10 cases), kidney (10 cases), mediastinum (8 cases), gall bladder (8 cases) etc.
  • The aim of this study was to evaluate the overall utility of ultrasonographic guided FNAC in the diagnosis of abdominal and thoracic lesions.
  • In 264 cases (82.5%), FNAC was diagnostic with commonest diagnosis being malignant neoplasm (70.0%).
  • In liver, Metastatic adenocarcinoma is the commonest tumor, while in lung; the commonest lesion is non-small cell carcinoma.
  • Benign neoplasm (3.1%) and non neoplastic lesion (9.4%) were also diagnosed by FNAC.
  • [MeSH-major] Neoplasms / diagnosis. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677604.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


33. Zaydfudim V, Feurer ID, Wright JK, Pinson CW: The impact of tumor extent (T stage) and lymph node involvement (N stage) on survival after surgical resection for gallbladder adenocarcinoma. HPB (Oxford); 2008;10(6):420-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of tumor extent (T stage) and lymph node involvement (N stage) on survival after surgical resection for gallbladder adenocarcinoma.
  • INTRODUCTION: Tumor extent (T stage) and lymph node involvement (N stage) have a known combined negative effect on survival in patients with gallbladder adenocarcinoma, but the independent effects of these factors have been less well described.
  • We investigated whether T stage and N stage independently predict survival after surgery for gallbladder adenocarcinoma.
  • METHODS: We queried the Surveillance, Epidemiology and End Results database for patients treated with surgical resection for gallbladder adenocarcinoma between 1988 and 2004.
  • CONCLUSIONS: Tumor extent and lymph node metastases are independent predictors of survival after surgical resection for gallbladder adenocarcinoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2008 Mar;34(3):306-12 [17964753.001]
  • [Cites] Br J Surg. 2000 Apr;87(4):418-22 [10759735.001]
  • [Cites] J Gastrointest Surg. 2007 May;11(5):671-81 [17468929.001]
  • [Cites] J Gastrointest Surg. 2007 Feb;11(2):158-65 [17390167.001]
  • [Cites] Surg Oncol Clin N Am. 2007 Jan;16(1):221-32 [17336245.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):827-32 [17109082.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):833-40 [17103074.001]
  • [Cites] J Surg Oncol. 2006 Jun 15;93(8):670-81 [16724356.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):395-6 [15729061.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):385-94 [15729060.001]
  • [Cites] Surgery. 1999 Mar;125(3):250-6 [10076608.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2618-28 [9874470.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):892-9 [9041150.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):639-46 [8916879.001]
  • [Cites] Biometrics. 1973 Sep;29(3):579-84 [4793138.001]
  • [Cites] Ann Surg. 2003 Apr;237(4):509-14 [12677147.001]
  • [Cites] Am Surg. 2001 Nov;67(11):1041-7 [11730220.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):557-69 [10998654.001]
  • [Cites] J Surg Oncol. 2007 Jul 1;96(1):8-13 [17516546.001]
  • (PMID = 19088928.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] ENG
  • [Grant] United States / AHRQ HHS / HS / T32 HS013833
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2597319
  • [Keywords] NOTNLM ; SEER registry / gallbladder cancer / lymph node metastases / survival / tumor extent
  •  go-up   go-down


34. Bianchi C, Bianchi T, Ramani L: Malignant mesothelioma of the pleura and other malignancies in the same patient. Tumori; 2007 Jan-Feb;93(1):19-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma of the pleura and other malignancies in the same patient.
  • METHODS: In the period October 1979-June 2002, 215 cases of malignant pleural mesothelioma were diagnosed at the Hospital of Monfalcone, Italy.
  • The most frequent additional malignancies were prostate adenocarcinoma (7 cases), non-Hodgkin lymphoma or chronic lymphocytic leukaemia (5 cases), bladder carcinoma (4 cases), kidney carcinoma (4 cases), large bowel carcinoma (4 cases), and liver cell carcinoma (4 cases).

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17455866.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


35. Kou T, Marusawa H, Kinoshita K, Endo Y, Okazaki IM, Ueda Y, Kodama Y, Haga H, Ikai I, Chiba T: Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int J Cancer; 2007 Feb 1;120(3):469-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Notably, we found that the transgenic mice overexpressing AID developed lung adenocarcinoma and hepatocellular carcinoma (HCC), suggesting that ectopic expression of AID can lead to tumorigenesis in epithelial tissues as well.
  • To examine the involvement of AID in the development of human HCC, we analyzed the AID expression and its correlation with mutation frequencies of the p53 gene in liver tissues from 51 patients who underwent resection of primary HCCs.
  • Only trace amounts of AID transcripts were detected in the normal liver; however, endogenous AID was significantly upregulated in both HCC and surrounding noncancerous liver tissues with underlying chronic hepatitis or liver cirrhosis (p < 0.05).
  • Most liver tissues with underlying chronic inflammation with endogenous AID upregulation already contained multiple genetic changes in the p53 gene.
  • Our findings suggest that the aberrant expression of AID is observed in human hepatocytes with several pathological settings, including chronic liver disease and HCC, which might enhance the genetic susceptibility to mutagenesis leading to hepatocarcinogenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Cytidine Deaminase / genetics. Hepatocytes / metabolism. Liver Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066440.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; 0 / Tumor Suppressor Protein p53; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


36. Bajaj V, Singhmar P, Kumar A: Promoter characterization and regulation of expression of an imprinted gene SLC22A18AS. Gene; 2008 Nov 15;424(1-2):40-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma. Base Sequence. Cell Line. Cell Line, Tumor. DNA / genetics. DNA / isolation & purification. DNA Methylation. Genes, Reporter. Genome, Human. Humans. Liver Neoplasms. Lung Neoplasms. Molecular Sequence Data. Oligonucleotide Array Sequence Analysis. RNA / genetics. RNA / isolation & purification. RNA, Messenger / genetics. Transcription Factors / metabolism. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721868.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / SLC22A18AS protein, human; 0 / Transcription Factors; 63231-63-0 / RNA; 9007-49-2 / DNA
  •  go-up   go-down


37. Ying-Tao Z, Yi-Ping G, Lu-Sheng S, Yi-Li W: Proteomic analysis of differentially expressed proteins between metastatic and non-metastatic human colorectal carcinoma cell lines. Eur J Gastroenterol Hepatol; 2005 Jul;17(7):725-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Two-dimensional gel electrophoresis (2-DE) was applied to separate the total proteins of cells.
  • The silver-stained gels were analysed by 2-DE software Image Master 2D Elite.
  • [MeSH-major] Adenocarcinoma / chemistry. Colorectal Neoplasms / chemistry. Neoplasm Proteins / analysis. Proteomics / methods
  • [MeSH-minor] Cell Line, Tumor. Electrophoresis, Gel, Two-Dimensional / methods. Humans. Liver Neoplasms / secondary. Peptide Mapping / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods


38. Saka M, Katai H, Fukagawa T, Nijjar R, Sano T: Recurrence in early gastric cancer with lymph node metastasis. Gastric Cancer; 2008;11(4):214-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common site of recurrence was lymph node (37%), followed by liver (21%).
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Signet Ring Cell / secondary. Lymphatic Metastasis. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aging. Analysis of Variance. Female. Gastrectomy. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplastic Cells, Circulating. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2767-73 [15199090.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2282-7 [12805327.001]
  • [Cites] Br J Surg. 2007 Dec;94(12):1468-76 [17948223.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):401-5 [11986193.001]
  • [Cites] Jpn J Clin Oncol. 2001 Oct;31(10):495-9 [11696619.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3174-8 [8242540.001]
  • [Cites] Br J Surg. 2002 Aug;89(8):1035-42 [12153632.001]
  • [Cites] Jpn J Clin Oncol. 2003 May;33(5):209-14 [12865463.001]
  • [Cites] Surgery. 1989 May;105(5):585-92 [2705096.001]
  • [Cites] Ann Surg Oncol. 2001 Aug;8(7):605-10 [11508623.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Br J Surg. 2005 Feb;92(2):235-9 [15609385.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] J Am Coll Surg. 2005 Jan;200(1):15-9 [15631915.001]
  • [Cites] Langenbecks Arch Surg. 2004 Apr;389(2):69-74 [14985987.001]
  • [Cites] Gastric Cancer. 2001;4(2):54-9 [11706761.001]
  • [Cites] Lancet. 1999 Jul 24;354(9175):273-7 [10440302.001]
  • [Cites] Dig Surg. 2003;20(2):148-53 [12686784.001]
  • (PMID = 19132483.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


39. Chen Y, Qiu Z, Kamruzzaman A, Snodgrass T, Scarfe A, Bryant HE: Survival of metastatic colorectal cancer patients treated with chemotherapy in Alberta (1995-2004). Support Care Cancer; 2010 Feb;18(2):217-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / mortality
  • [MeSH-minor] Aged. Alberta / epidemiology. Female. Humans. Liver Neoplasms / mortality. Liver Neoplasms / secondary. Male. Palliative Care / statistics & numerical data. Registries. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CMAJ. 2001 Jul 24;165(2):206-8 [11501466.001]
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1727-35 [17437502.001]
  • [Cites] Cancer Treat Rev. 2006 Nov;32(7):557-71 [16935430.001]
  • [Cites] Health Rep. 2006 May;17(2):19-30 [16716033.001]
  • [Cites] Dig Surg. 2005;22(6):401-14 [16479107.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27 [16204691.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1B):563-76 [15816629.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4626-31 [15542812.001]
  • [Cites] Cancer. 1996 Nov 1;78(9):2004-10 [8909323.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2214-22 [14522381.001]
  • [Cites] Cardiovasc Drugs Ther. 2002 Jan;16(1):75-7 [12085983.001]
  • (PMID = 19440737.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2795864
  •  go-up   go-down


40. Koukoutsis I, Tamijmarane A, Bellagamba R, Bramhall S, Buckels J, Mirza D: The impact of splenectomy on outcomes after distal and total pancreatectomy. World J Surg Oncol; 2007;5:61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients, who underwent distal and total pancreatectomy without histologically proven adenocarcinoma, or extrapancreatic disease, were included in the cohort which was divided into splenectomy and no splenectomy groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1999 Mar;188(3):255-60 [10065814.001]
  • [Cites] Surgery. 1996 Nov;120(5):885-90 [8909526.001]
  • [Cites] Br J Surg. 1999 Jul;86(7):895-8 [10417561.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):164-8 [11822953.001]
  • [Cites] Chang Gung Med J. 2002 Jan;25(1):23-8 [11926583.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):148-52 [11941940.001]
  • [Cites] Am J Surg. 2002 Mar;183(3):237-41 [11943118.001]
  • [Cites] Ann Surg. 2003 Jan;237(1):57-65 [12496531.001]
  • [Cites] HPB Surg. 1992 Jun;5(4):251-9; discussion 259-60 [1356420.001]
  • [Cites] Pancreas. 2004 Mar;28(2):207-10 [15028954.001]
  • [Cites] Surgery. 2005 Feb;137(2):180-5 [15674199.001]
  • [Cites] Arch Surg. 1990 Sep;125(9):1109-13 [1698047.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):976-9 [1913121.001]
  • [Cites] Br J Surg. 1991 Sep;78(9):1031-8 [1933181.001]
  • [Cites] Arch Surg. 1989 May;124(5):571-3 [2712699.001]
  • [Cites] Am Surg. 1989 Jan;55(1):21-5 [2913905.001]
  • [Cites] Ann Surg. 1989 Mar;209(3):273-8 [2923514.001]
  • [Cites] Arch Surg. 1988 May;123(5):550-3 [3358679.001]
  • [Cites] Surg Gynecol Obstet. 1987 Dec;165(6):507-14 [3686316.001]
  • [Cites] Br J Surg. 1985 Oct;72(10):801-3 [4041711.001]
  • [Cites] Br J Surg. 1984 Mar;71(3):173-80 [6697116.001]
  • [Cites] Surg Clin North Am. 1981 Feb;61(1):135-55 [7010637.001]
  • [Cites] Surgery. 1995 Jan;117(1):26-31 [7809832.001]
  • [Cites] J Am Coll Surg. 1999 May;188(5):516-21 [10235580.001]
  • (PMID = 17543130.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1891298
  •  go-up   go-down


41. Rubio CA: Cell proliferation at the leading invasive front of colonic carcinomas. Preliminary observations. Anticancer Res; 2006 May-Jun;26(3B):2275-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology
  • [MeSH-minor] Cell Growth Processes / physiology. Humans. Ki-67 Antigen / biosynthesis. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821601.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


42. Tazi N, Le Thi Huong D, Bodaghi B, Rixe O, Lehoang P, Piette JC: [Choroidal metastasis revealing pulmonary adenocarcinoma]. Rev Med Interne; 2006 Sep;27(9):699-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroidal metastasis revealing pulmonary adenocarcinoma].
  • He presented with visual decrease and metamorphopsia that lead to the diagnosis of a metastatic adenocarcinoma of the lung (bone, liver, choroid, nodles).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872723.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


43. Ward J: New MR techniques for the detection of liver metastases. Cancer Imaging; 2006;6:33-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New MR techniques for the detection of liver metastases.
  • It is well established that hepatic resection improves the long-term prognosis of many patients with liver metastases.
  • However, incomplete resection does not prolong survival, so knowledge of the exact extent of intra-hepatic disease is crucially important in determining patient management and outcome.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Artifacts. Contrast Media. Cysts / pathology. Equipment Design. Fatty Liver / chemically induced. Fatty Liver / pathology. Forecasting. Gadolinium. Gadolinium DTPA. Humans. Imaging, Three-Dimensional. Meglumine / analogs & derivatives. Organometallic Compounds

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright International Cancer Imaging Society.
  • [Cites] Radiology. 2002 May;223(2):525-31 [11997563.001]
  • [Cites] Eur J Surg Oncol. 2002 Sep;28(6):645-51 [12359202.001]
  • [Cites] Eur Radiol. 2003 Feb;13(2):262-72 [12598989.001]
  • [Cites] Eur Radiol. 2003 Jun;13(6):1266-76 [12764641.001]
  • [Cites] Dig Surg. 2003;20(4):321-5 [12806198.001]
  • [Cites] Radiology. 2003 Sep;228(3):719-26 [12881583.001]
  • [Cites] Radiology. 2003 Sep;228(3):709-18 [12888620.001]
  • [Cites] Abdom Imaging. 2003 Jul-Aug;28(4):525-30 [14580096.001]
  • [Cites] Radiology. 2004 Jan;230(1):266-75 [14695400.001]
  • [Cites] Dig Dis Sci. 2005 Mar;50(3):533-7 [15810637.001]
  • [Cites] Radiology. 2005 Oct;237(1):170-80 [16126930.001]
  • [Cites] Eur Radiol. 2004 Jan;14(1):5-13 [14600778.001]
  • [Cites] Eur Radiol. 2004 Jan;14(1):14-20 [14730384.001]
  • [Cites] Eur Radiol. 2004 Apr;14(4):559-78 [14986050.001]
  • [Cites] J Magn Reson Imaging. 2004 Oct;20(4):612-21 [15390224.001]
  • [Cites] J Magn Reson Imaging. 2004 Oct;20(4):640-7 [15390231.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):326-30 [2021849.001]
  • [Cites] Radiology. 1992 Oct;185(1):1-11 [1523289.001]
  • [Cites] Radiology. 1995 Apr;195(1):113-6 [7892449.001]
  • [Cites] Radiology. 1995 Aug;196(2):471-8 [7617863.001]
  • [Cites] AJR Am J Roentgenol. 1996 Jan;166(1):91-5 [8571914.001]
  • [Cites] AJR Am J Roentgenol. 1996 Feb;166(2):369-74 [8553950.001]
  • [Cites] Radiology. 1999 Oct;213(1):86-91 [10540645.001]
  • [Cites] Acta Radiol. 1999 Nov;40(6):628-35 [10598852.001]
  • [Cites] Radiology. 2000 Jan;214(1):159-66 [10644117.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):471-9 [10749606.001]
  • [Cites] Radiology. 2000 May;215(2):365-72 [10796909.001]
  • [Cites] Radiology. 2000 Jun;215(3):727-36 [10831691.001]
  • [Cites] J Magn Reson Imaging. 2000 Jun;11(6):665-72 [10862066.001]
  • [Cites] Radiology. 2000 Oct;217(1):152-8 [11012438.001]
  • [Cites] Radiology. 2001 Jan;218(1):55-60 [11152779.001]
  • [Cites] Radiology. 2001 Feb;218(2):556-61 [11161178.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):887-94 [11521792.001]
  • [Cites] Invest Radiol. 2001 Nov;36(11):632-41 [11606840.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2001 Nov;9(4):717-43, vi [11694435.001]
  • [Cites] Magn Reson Med. 2002 Jan;47(1):135-42 [11754452.001]
  • [Cites] Radiology. 1996 Aug;200(2):459-64 [8685342.001]
  • [Cites] Radiology. 1996 Sep;200(3):785-92 [8756932.001]
  • [Cites] Radiology. 1997 Jan;202(1):268-73 [8988222.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):490-3 [9068476.001]
  • [Cites] Radiology. 1997 Jun;203(3):759-65 [9169701.001]
  • [Cites] Surgery. 1997 Jun;121(6):625-32 [9186462.001]
  • [Cites] Radiology. 1997 Aug;204(2):513-20 [9240546.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):977-80 [9240140.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1341-7 [9574613.001]
  • [Cites] Radiology. 1999 Jan;210(1):89-96 [9885592.001]
  • [Cites] J Magn Reson Imaging. 1999 Jan;9(1):87-92 [10030655.001]
  • [Cites] Magn Reson Imaging. 1999 Apr;17(3):383-92 [10195581.001]
  • [Cites] Radiology. 1999 Feb;210(2):459-66 [10207430.001]
  • [Cites] Am J Surg. 1999 Apr;177(4):294-8 [10326846.001]
  • [Cites] Eur Radiol. 2005 Feb;15(2):220-8 [15624108.001]
  • [Cites] Br J Radiol. 2005 Feb;78(926):105-9 [15681320.001]
  • [Cites] AJR Am J Roentgenol. 2005 Mar;184(3):842-6 [15728606.001]
  • [Cites] J Magn Reson Imaging. 2005 Mar;21(3):219-29 [15723376.001]
  • (PMID = 16766267.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadolinium ethoxybenzyl DTPA; 15G12L5X8K / gadobenic acid; 6HG8UB2MUY / Meglumine; AU0V1LM3JT / Gadolinium; K2I13DR72L / Gadolinium DTPA
  • [Number-of-references] 56
  • [Other-IDs] NLM/ PMC1693769
  •  go-up   go-down


44. Joo HJ, Kim GH, Jeon WJ, Chae HB, Park SM, Youn SJ, Choi JW, Sung R: Metachronous bile duct cancer nine years after resection of gallbladder cancer. World J Gastroenterol; 2009 Jul 21;15(27):3440-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the age of 65 years, the patient underwent a cholecystectomy and resection of the liver bed for gallbladder cancer.
  • This was a well-differentiated adenocarcinoma, with negative resection margins (T2N0M0, stage IB).
  • We diagnosed this lesion as a perihilar bile duct cancer, Bismuth type IIIa, and performed bile duct excision, right hepatic lobectomy and Roux-en-Y hepaticojejunostomy.
  • The histological diagnosis was a well-differentiated adenocarcinoma with one regional lymph node metastasis (T1N1M0, stage IIB).
  • [MeSH-major] Adenocarcinoma / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Gallbladder Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(4):374-8 [11521184.001]
  • [Cites] J Gastroenterol. 2001 Nov;36(11):787-9 [11757753.001]
  • [Cites] Endoscopy. 2003 Jun;35(6):538-41 [12783356.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):664-7 [15143888.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):280-5 [15368115.001]
  • [Cites] Am J Surg. 1990 Apr;159(4):386-8 [2180336.001]
  • [Cites] Langenbecks Arch Surg. 2009 Jan;394(1):159-69 [18500533.001]
  • [Cites] Jpn J Clin Oncol. 1999 Jul;29(7):353-5 [10470661.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):15-25 [16391368.001]
  • [Cites] Jpn J Clin Oncol. 2006 Oct;36(10):638-42 [16908513.001]
  • [Cites] Scand J Gastroenterol. 2007 Oct;42(10):1265-8 [17852857.001]
  • [Cites] J Surg Oncol. 2008 Aug 1;98(2):106-10 [18452218.001]
  • [Cites] J Surg Oncol. 1997 Aug;65(4):258-62 [9274790.001]
  • (PMID = 19610150.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2712910
  •  go-up   go-down


45. Tsavaris N, Kosmas C, Kopterides P, Tsikalakis D, Skopelitis H, Sakelaridi F, Papadoniou N, Tzivras M, Balatsos V, Koufos C, Archimandritis A: Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma. World J Gastroenterol; 2005 Dec 7;11(45):7174-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma.
  • METHODS: We measured the serum levels of CRP, TRF, A2M, CER, AAG, P-ALB, and RBP in 153 preoperative patients (93 males; mean age: 63.1+/-11.3 years) with non-cardia gastric adenocarcinoma and 19 healthy subjects.
  • [MeSH-major] Adenocarcinoma / complications. Helicobacter Infections / complications. Helicobacter pylori. Stomach Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437667.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Biomarkers, Tumor; 0 / Retinol-Binding Proteins
  • [Other-IDs] NLM/ PMC4725071
  •  go-up   go-down


46. DeLappe EM, Truong MT, Bruzzi JF, Swisher SG, Rohren EM: Hepatic radiation injury mimicking a metastasis on positron-emission tomography/computed tomography in a patient with esophageal carcinoma. J Thorac Oncol; 2009 Nov;4(11):1442-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic radiation injury mimicking a metastasis on positron-emission tomography/computed tomography in a patient with esophageal carcinoma.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Esophageal Neoplasms / radiotherapy. Liver / radiation effects. Positron-Emission Tomography / methods. Radiation Injuries / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Dose-Response Relationship, Radiation. Humans. Male. Middle Aged. Neoplasm Metastasis / diagnosis

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861910.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Nishimura R, Mogami H, Teramoto N, Tanada M, Kurita A: Inflammatory pseudotumor of the liver in a patient with early gastric cancer: CT-histopathological correlation. Jpn J Clin Oncol; 2005 Apr;35(4):218-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory pseudotumor of the liver in a patient with early gastric cancer: CT-histopathological correlation.
  • A case of inflammatory pseudotumor (IPT) of the liver associated with early gastric cancer is reported.
  • Intravenous contrast-enhanced computed tomography (CT) showed a large, irregularly shaped mass lesion in the left lobe of the liver.
  • The gastric cancer was a papillary adenocarcinoma limited to the mucosa.
  • The resected liver tumor measured 5.5 x 5.0 x 4.0 cm, and its cut surface revealed a well-circumscribed mass divided into lobules by fibrous tissue.
  • The CT findings of delayed peripheral rim-like or septal enhancement of the hepatic tumor may be a specific finding of IPT.
  • [MeSH-major] Adenocarcinoma, Papillary / complications. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / radiography. Liver Diseases / pathology. Liver Diseases / radiography. Stomach Neoplasms / complications. Tomography, X-Ray Computed


48. Bralet MP, Paule B, Falissard B, Adam R, Guettier C: Immunohistochemical variability of epidermal growth factor receptor (EGFR) in liver metastases from colonic carcinomas. Histopathology; 2007 Jan;50(2):210-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical variability of epidermal growth factor receptor (EGFR) in liver metastases from colonic carcinomas.
  • AIMS: To follow and compare immunohistochemical expression of epidermal growth factor receptor (EGFR) in tumour cells during the entire natural history of colonic carcinoma, from primary tumour to paired lymph node and sequentially resected liver metastases; and to test interobserver reproducibility of EGFR analysis.
  • METHODS AND RESULTS: Forty patients had resection of colonic adenocarcinoma (27 with metastatic lymph nodes) and at least one partial hepatectomy (PH) for liver metastases; a second and a third PH were performed, respectively, in 14 and three patients; seven patients had tumour liver biopsy.
  • EGFR expression (membranous staining detected in > or = 1% of tumour cells) was detected in 38/40 colonic carcinomas, 23/26 lymph nodes and 51/64 liver metastases.
  • Discrepancies were found in EGFR status between liver and lymph node (23%) and among the different liver samples (31%).
  • Interobserver agreement was very good (intraclass correlation coefficients of 0.81, 0.91 and 0.85, respectively, for interpretation of staining in colon, lymph node and liver metastases).
  • [MeSH-major] Carcinoma / metabolism. Colonic Neoplasms / metabolism. Immunohistochemistry. Liver Neoplasms / secondary. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222249.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


49. Cabillic F, Toutirais O, Lavoué V, de La Pintière CT, Daniel P, Rioux-Leclerc N, Turlin B, Mönkkönen H, Mönkkönen J, Boudjema K, Catros V, Bouet-Toussaint F: Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunol Immunother; 2010 Nov;59(11):1611-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatocellular carcinoma (HCC) and colorectal carcinoma with hepatic metastases (mCRC) are cancers with poor prognosis and limited therapeutic options.
  • [MeSH-major] Colorectal Neoplasms / therapy. Dendritic Cells / immunology. Diphosphonates / pharmacology. Imidazoles / pharmacology. Immunotherapy, Adoptive. Liver Neoplasms / therapy. Receptors, Antigen, T-Cell, gamma-delta / metabolism
  • [MeSH-minor] Adenocarcinoma / immunology. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Aged. Blotting, Western. Bone Density Conservation Agents / pharmacology. Carcinoma, Hepatocellular / immunology. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / therapy. Cell Differentiation. Cell Proliferation. Coculture Techniques. Cytotoxicity, Immunologic. Diphosphates / pharmacology. Female. Flow Cytometry. Hemiterpenes / metabolism. Humans. Male. Middle Aged. Organophosphorus Compounds / metabolism. T-Lymphocyte Subsets / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20582413.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphates; 0 / Diphosphonates; 0 / Hemiterpenes; 0 / Imidazoles; 0 / Organophosphorus Compounds; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / T-cell receptor Vdelta2, human; 0 / T-cell receptor Vgamma9, human; 0 / bromohydrin pyrophosphate; 358-71-4 / isopentenyl pyrophosphate; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


50. Egawa T, Nagashima A, Kitano M, Doi M, Hayashi S, Yoshii H: [A case of an increase in resectability with preoperative chemotherapy TS-1 combined with CPT-11 for unresectable rectal cancer in downstaging]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1771-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was diagnosed with rectal cancer using colonoscopy and also diagnosed with unresectable rectal cancer because abdominal CT revealed metastases to the liver, lung and lymph node located porta hepatis.
  • Pathological efficacy was Grade 1a at lymph node metastasis and Grade 3 at liver metastasis.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315936.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


51. Yamaguchi Y, Sawamura A, Minami K: Clinical trial of low-dose leucovorin plus 5-fluorouracil for patients with metastatic colorectal cancer. Hepatogastroenterology; 2007 Jul-Aug;54(77):1394-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient with lung, liver, and parailiac lymph node metastasis showed a complete response and survived for more than 6 years with tumor-free status.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antimetabolites, Antineoplastic / therapeutic use. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Fluorouracil / therapeutic use. Leucovorin / administration & dosage. Vitamin B Complex / administration & dosage

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - B Vitamins.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708262.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


52. Wiseman JM, Puolitaival SM, Takáts Z, Cooks RG, Caprioli RM: Mass spectrometric profiling of intact biological tissue by using desorption electrospray ionization. Angew Chem Int Ed Engl; 2005 Nov 4;44(43):7094-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / chemistry. Lipids / chemistry. Liver Neoplasms / chemistry. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Adipose Tissue / chemistry. Animals. Brain. Humans. Liver / chemistry. Liver / pathology. Mice. Pancreas / chemistry. Rats

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259018.001).
  • [ISSN] 1433-7851
  • [Journal-full-title] Angewandte Chemie (International ed. in English)
  • [ISO-abbreviation] Angew. Chem. Int. Ed. Engl.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / 5R01 GM58008-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Lipids
  •  go-up   go-down


53. Saghir SA, Charles GD, Bartels MJ, Kan LH, Dryzga MD, Brzak KA, Clark AJ: Mechanism of trifluralin-induced thyroid tumors in rats. Toxicol Lett; 2008 Jul 30;180(1):38-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trifluralin-induced total hepatic UGT enzymes (2.4-fold) and mRNA expression of selected hepatic UGT isozymes (UGT1A1, 1.4-fold; UGT1A6, 6.4-fold; UGT2B1, 3.7-fold).
  • [MeSH-major] Adenocarcinoma, Follicular / chemically induced. Herbicides / toxicity. Thyroid Gland / drug effects. Thyroid Neoplasms / chemically induced. Trifluralin / toxicity
  • [MeSH-minor] Administration, Oral. Animal Feed. Animals. Dose-Response Relationship, Drug. Gene Expression Regulation, Enzymologic / drug effects. Glucuronosyltransferase / genetics. Glucuronosyltransferase / metabolism. Liver / drug effects. Liver / metabolism. Liver / pathology. Male. Microsomes, Liver / drug effects. Microsomes, Liver / enzymology. Organ Size / drug effects. RNA, Messenger / metabolism. Rats. Rats, Inbred F344. Thyrotropin / blood. Thyroxine / blood. Triiodothyronine / blood

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. TRIFLURALIN .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18582544.001).
  • [ISSN] 0378-4274
  • [Journal-full-title] Toxicology letters
  • [ISO-abbreviation] Toxicol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Herbicides; 0 / RNA, Messenger; 06LU7C9H1V / Triiodothyronine; 9002-71-5 / Thyrotropin; C8BX46QL7K / Trifluralin; EC 2.4.1.17 / Glucuronosyltransferase; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


54. Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, Ranki T, Sarkioja M, Kangasniemi L, Hemminki A: Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther; 2005 Aug;12(15):1198-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have evaluated the use of Ad5/3-Delta24, a serotype 3 receptor targeted Rb/p16 pathway selective CRAd, in combination with gemcitabine against human ovarian adenocarcinoma.
  • Mice remained free from intraperitoneal disease, but some succumbed to treatment-related hepatic or bone marrow toxicity.
  • [MeSH-major] Adenocarcinoma / therapy. Antiviral Agents / therapeutic use. Deoxycytidine / analogs & derivatives. Genetic Therapy / methods. Oncolytic Virotherapy / methods. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adenovirus E1A Proteins / genetics. Adenoviruses, Human / genetics. Animals. Bone Marrow Cells / pathology. Bone Marrow Cells / virology. Cell Line, Tumor. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Liver / pathology. Liver / virology. Mice. Neoplasms, Experimental. Oncolytic Viruses. Virus Replication

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800658.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / Antiviral Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


55. Mainenti PP, Mancini M, Mainolfi C, Camera L, Maurea S, Manchia A, Tanga M, Persico F, Addeo P, D'Antonio D, Speranza A, Bucci L, Persico G, Pace L, Salvatore M: Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents. Abdom Imaging; 2010 Oct;35(5):511-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents.
  • BACKGROUND: To compare contrast-enhanced US (CE-US), multidetector-CT (MDCT), 1.5 Tesla MR with extra-cellular (Gd-enhanced) and intracellular (SPIO-enhanced) contrast agents and PET/CT, in the detection of hepatic metastases from colorectal cancer.
  • MATERIALS AND METHODS: A total of 34 patients with colo-rectal adenocarcinoma underwent preoperatively CE-US, MDCT, Gd- and SPIO-enhanced MR imaging (MRI), and PET/CT.
  • RESULTS: A total of 57 hepatic lesions were identified: 11 hemangiomas, 29 cysts, 1 focal fatty liver, 16 metastases (dimensional distribution: 5/16 < 5 mm; 3/16 between 5 mm and <10 mm; 8/16 ≥ 10 mm).
  • CONCLUSIONS: Gd- and SPIO-enhanced MRI seem to be the most accurate modality in the identification of liver metastases from colo-rectal carcinoma.
  • PET/CT shows a trend to perform better than the other modalities in the identification of patients with liver metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Contrast Media. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods. Ultrasonography / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dextrans. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Gadolinium DTPA. Humans. Iohexol / analogs & derivatives. Magnetite Nanoparticles. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. ROC Curve. Radiopharmaceuticals. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • Hazardous Substances Data Bank. Ferumoxides .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562412.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Magnetite Nanoparticles; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide; G6N3J05W84 / ferumoxides; K2I13DR72L / Gadolinium DTPA; K3R6ZDH4DU / Dextrans
  •  go-up   go-down


56. Kim MS, Jeong EG, Yoo NJ, Lee SH: Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer; 2008 May 6;98(9):1533-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Acute Disease. Adenocarcinoma / genetics. Adult. Aged. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Carcinoma, Hepatocellular / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Colorectal Neoplasms / genetics. DNA Mutational Analysis. Female. Glutamic Acid. Humans. Liver Neoplasms / genetics. Lung Neoplasms / genetics. Lysine. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Stomach Neoplasms / genetics


57. Kato T, Nakashima M, Yoshimura K, Imao M, Goto H, Yasuda S, Sano K: [A case of lung adenocarcinoma of the lung with disappearance of brain metastasis by re-treatment with gefitinib]. Nihon Kokyuki Gakkai Zasshi; 2005 Nov;43(11):700-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of lung adenocarcinoma of the lung with disappearance of brain metastasis by re-treatment with gefitinib].
  • CASE: A 40-year-old man was given a diagnosis of adenocarcinoma of lung (c-T2N3M1).
  • Reduction of the primary tumor, brain metastasis, pulmonary metastasis and liver metastasis was seen.
  • Recurrence of pulmonary metastasis and liver metastasis was discovered 8 months after treatment with gefitinib.
  • However, primary tumor, pulmonary metastasis and liver metastasis progressed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Lung Neoplasms / pathology. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Brain / radiography. Combined Modality Therapy. Cranial Irradiation. Humans. Liver Neoplasms / secondary. Male. Remission Induction. Retreatment. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366371.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


58. Shrikhande SV, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I, Schmidt J, Friess H, Büchler MW: Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol; 2007 Jan;14(1):118-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic resection for M1 pancreatic ductal adenocarcinoma.
  • BACKGROUND: Improved safety of pancreatic surgery has led to consideration of more aggressive approaches, such as resection for primary pancreatic ductal adenocarcinoma (PDAC) with metastatic disease (M1).
  • METHODS: A total of 29 patients who underwent pancreatic resection with resection of associated metastatic disease (interaortocaval lymph node dissection, liver resection, and/or multiorgan resections) were retrospectively identified from a database of 316 R0/R1 pancreatic resections for PDAC.
  • The median survival in those with metastatic interaortocaval lymph nodes was 27 months (95% CI, 9.6-27.0), whereas it was 11.4 months (95% CI, 7.8-16.5) and 12.9 months (95% CI, 7.2-20.5) for those with liver and peritoneal metastases, respectively.
  • Resection of liver and peritoneal metastases, although safe in this series, cannot be generally recommended until further controlled trials can be conducted.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066229.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Vats HS, Banerjee TK, Resnick J, Khan Q: Esophageal adenocarcinoma arising from Barrett's dysplasia: a case report of double occurrence and prolonged survival after chemotherapy. Clin Med Res; 2006 Sep;4(3):184-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal adenocarcinoma arising from Barrett's dysplasia: a case report of double occurrence and prolonged survival after chemotherapy.
  • A relatively young patient with chronic gastroesophageal reflux disease (GERD), obesity, smoking, and alcohol intake presented with widespread metastatic disease in lymph nodes, liver and lungs from a lower esophageal adenocarcinoma extending into the gastroesophageal junction associated with Barrett's mucosa and dysplasia.A complete response was achieved with six cycles of chemotherapy that sustained for more than 4 years without further recurrence.
  • Unfortunately, there was presence of esophageal metaplasia after complete response which eventually converted to low to high grade dysplasia and ultimately to a second primary localized lower esophageal adenocarcinoma that was treated with thoracoabdominal esophagectomy and lymphadenectomy.
  • The pathogenesis of a recent increase in the incidence of GERD, Barrett's esophagus and lower esophageal adenocarcinoma are discussed.
  • Lower esophageal adenocarcinoma is frequently associated with Barrett's high-grade dysplasia.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / complications. Esophageal Neoplasms / etiology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Gastroesophageal Reflux / complications. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2004 Jul;11(7):641-3 [15197008.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jan;19(1):4-12 [14675236.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):104-9 [7707381.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Am J Gastroenterol. 1998 Apr;93(4):536-41 [9576444.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1826-34 [9586897.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] Gut. 1998 Sep;43(3):327-33 [9863476.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):664-72 [15763640.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1554-66 [15887151.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jun;3(6):529-37 [15952094.001]
  • [Cites] CA Cancer J Clin. 2005 Nov-Dec;55(6):334-51 [16282279.001]
  • [Cites] Oncologist. 2004;9(2):147-59 [15047919.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1355-62 [11374668.001]
  • [Cites] Am J Med. 2001 Jul;111(1):33-7 [11448658.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Aug;15(8):1087-100 [11472311.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1167-74 [11870157.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):376-84; discussion 384-5 [12192324.001]
  • [Cites] Surgery. 2003 Jan;133(1):24-31 [12563234.001]
  • [Cites] Cancer Treat Rev. 2003 Dec;29(6):525-32 [14585262.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • (PMID = 16988098.001).
  • [ISSN] 1539-4182
  • [Journal-full-title] Clinical medicine & research
  • [ISO-abbreviation] Clin Med Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC1570486
  •  go-up   go-down


60. Akita H, Watanabe Y, Ishida H, Nakaguchi K, Okino T, Kabuto T: A foreign body granuloma after gastric perforation mimicking peritoneal dissemination of gastric cancer: report of a case. Surg Today; 2009;39(9):795-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient presented with a severe attack of acute upper abdominal pain, was admitted to the hospital, and thereafter underwent an immediate laparotomy due to a diagnosis of an upper gastrointestinal perforation.
  • The pathological examination of biopsy specimens taken around the scar revealed well to poorly differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Granuloma, Foreign-Body / diagnosis. Stomach Neoplasms / diagnosis. Stomach Ulcer / surgery
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Neoplasm Seeding. Peritoneum / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1994 Sep-Oct;14(5B):2131-4 [7840512.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Apr;22(4):597-600 [17376061.001]
  • [Cites] Dig Liver Dis. 2007 Apr;39(4):368 [17298888.001]
  • [Cites] J Surg Oncol. 2002 Aug;80(4):181-5 [12210031.001]
  • [Cites] Dig Surg. 2006;23(4):217-23 [16874002.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):516-8 [9068483.001]
  • [Cites] J Am Coll Surg. 1994 Sep;179(3):299-304 [8069426.001]
  • [Cites] Br J Surg. 1996 May;83(5):672-4 [8689216.001]
  • [Cites] Arch Surg. 1995 Feb;130(2):177-81 [7531430.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):242-8 [8604903.001]
  • [Cites] Surg Today. 2008;38(6):552-4 [18516538.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):780-4 [11087645.001]
  • (PMID = 19779777.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Sprinzl MF, Schimanski CC, Moehler M, Schadmand-Fischer S, Galle PR, Kanzler S: Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer; 2006;6:190
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE PRESENTATION: We report a 69-year-old patient with non-resectable CC showing hepatic metastasis and peritoneal carcinomatosis.
  • Diagnosis was based on computed tomography, mini-laparoscopy and bioptic specimens.
  • Histology revealed an adenocarcinoma of the biliary tract with expression of epithelial growth factor receptor.
  • In parallel, Ca 19-9 serum levels, which were elevated 5-fold at time of diagnosis, returned to normal after 16 weeks of treatment.
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Cetuximab. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Liver Neoplasms / secondary. Male. Palliative Care. Quality of Life. Survival Analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2610-6 [15226328.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Am Surg. 2004 Sep;70(9):743-8; discussion 748-9 [15481288.001]
  • [Cites] J Biol Chem. 1984 Jun 25;259(12):7755-60 [6330079.001]
  • [Cites] Mol Biol Med. 1983 Dec;1(5):511-29 [6094961.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Apr;11(4):849-54 [3980281.001]
  • [Cites] Mol Biol Cell. 1993 Jan;4(1):121-33 [7680247.001]
  • [Cites] Anticancer Res. 1993 May-Jun;13(3):565-9 [8317885.001]
  • [Cites] Am J Clin Pathol. 1994 Dec;102(6):764-7 [7528468.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):171-7 [9921990.001]
  • [Cites] J Hepatol. 2004 Nov;41(5):808-14 [15519654.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii93-6 [15958484.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1980-7 [12743152.001]
  • (PMID = 16846514.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ PMC1564184
  •  go-up   go-down


62. Mouri T, Ogawa M, Mitsuyama Y, Yamagata T, Kosuge M, Ushigome T, Eto K, Watanabe M, Anazawa S, Yanaga K: [Multiple hepatic metastases of colon cancer responding to combined therapy with TS-1 and CPT-11--a case report]. Gan To Kagaku Ryoho; 2006 Aug;33(8):1171-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple hepatic metastases of colon cancer responding to combined therapy with TS-1 and CPT-11--a case report].
  • We treated a patient with multiple liver metastases arising from colon cancer in whom the metastatic tumors were responsive to treatment with the combination of TS-1 and CPT-11.
  • The patient was a 71-year-old woman with cancer of the ascending colon and metastatic hepatic tumors.
  • She had undergone surgery on July 28, 2004, and abdominal contrast CT scans obtained after discharge from hospital revealed numerous LDA (low-density areas) in both lobes of the liver.
  • After completion of 2 courses of chemotherapy, abdominal contrast CT scans revealed that most of the LDAs in both lobes of the liver had disappeared, and the patient was judged to have achieved PR.
  • This case suggests that the combination of TS-1 and CPT-11 may be an effective form of chemotherapy for the treatment of colon cancer with multiple hepatic metastases.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / pathology. Liver Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912543.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


63. Giuliani F, Molica S, Maiello E, Battaglia C, Gebbia V, Di Bisceglie M, Vinciarelli G, Gebbia N, Colucci G, Gruppo Oncologico dell' Italia Meridionale (prot. 2106): Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). Am J Clin Oncol; 2005 Dec;28(6):581-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of this study was to evaluate the activity and toxicity of a combination regimen of CPT-11 and mitomycin-c as second-line chemotherapy for pretreated patients with advanced, metastatic, or both, gastric adenocarcinoma.
  • Entry criteria included histologic/cytologic diagnosis of gastric adenocarcinoma, age 18 to 75 years, performance status > or =70 (Karnofsky scale), bi-dimensionally measurable disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Salvage Therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Disease-Free Survival. Drug Synergism. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Italy. Life Tables. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neutropenia / chemically induced. Neutropenia / drug therapy. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16317268.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 50SG953SK6 / Mitomycin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


64. Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M: Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res; 2005 Jul-Aug;25(4):3031-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We explored the hypothesis that intravenous infusion of Lipoplatin results in tumor targeting in four independent patient cases (one with hepatocellular adenocarcinoma, two with gastric cancer and one with colon cancer) who underwent Lipoplatin infusion followed by a prescheduled surgery approximately 20 h later.
  • Direct measurement of the platinum levels in specimens from the excised tumors and normal tissues showed that the total platinum levels were on average 10-50 times higher in malignant tissue compared to the adjacent normal tissue specimens; most effective targeting was observed in colon cancer, with an accumulation up to 200-fold higher in colon tumors compared to normal colon tissue.
  • In conclusion, Lipoplatin has the ability to preferentially concentrate in malignant tissue both of primary and metastatic origin following intravenous infusion to patients.
  • [MeSH-minor] Adipose Tissue / metabolism. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / metabolism. Colonic Neoplasms / drug therapy. Colonic Neoplasms / metabolism. Female. Humans. Infusions, Intravenous. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Stomach Neoplasms / drug therapy. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080562.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / lipoplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


65. Lin JC, Siu LK, Fung CP, Yeh KM, Chang FY: Nosocomial liver abscess caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. J Clin Microbiol; 2007 Jan;45(1):266-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nosocomial liver abscess caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.
  • A nosocomial pyogenic liver abscess caused by an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolate presented in a man with adenocarcinoma of the stomach.
  • The K. pneumoniae strain isolated from blood and liver aspirate cultures after antibiotic therapy for recurrent bacteremia was resistant to all extended-spectrum beta-lactams except imipenem and differed from K. pneumoniae strains causing community-acquired liver abscesses.
  • [MeSH-major] Cross Infection / microbiology. Klebsiella Infections / microbiology. Klebsiella pneumoniae / isolation & purification. Liver Abscess, Pyogenic / microbiology. beta-Lactamases / metabolism
  • [MeSH-minor] Adenocarcinoma / complications. Anti-Bacterial Agents / pharmacology. Anti-Bacterial Agents / therapeutic use. Bacteremia / drug therapy. Bacteremia / microbiology. Fatal Outcome. Humans. Male. Middle Aged. Stomach Neoplasms / complications. beta-Lactam Resistance

  • Genetic Alliance. consumer health - Klebsiella.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2000 Jun;181(6):2075-9 [10837197.001]
  • [Cites] Diagn Microbiol Infect Dis. 2000 Aug;37(4):279-84 [10974581.001]
  • [Cites] J Antimicrob Chemother. 2001 Jun;47(6):755-61 [11389107.001]
  • [Cites] Gut. 2002 Mar;50(3):420-4 [11839725.001]
  • [Cites] J Microbiol Immunol Infect. 2002 Mar;35(1):1-11 [11950113.001]
  • [Cites] Curr Opin Infect Dis. 2001 Dec;14(6):697-701 [11964887.001]
  • [Cites] Arch Intern Med. 2002 May 13;162(9):1021-7 [11996612.001]
  • [Cites] J Microbiol Immunol Infect. 2002 Jun;35(2):85-8 [12099340.001]
  • [Cites] Ann Intern Med. 2004 Jan 6;140(1):26-32 [14706969.001]
  • [Cites] J Exp Med. 2004 Mar 1;199(5):697-705 [14993253.001]
  • [Cites] J Formos Med Assoc. 1995 May;94(5):232-7 [7613255.001]
  • [Cites] J Infect Dis. 1996 Sep;174(3):529-36 [8769610.001]
  • [Cites] JAMA. 1999 Feb 10;281(6):517-23 [10022107.001]
  • [Cites] Clin Infect Dis. 2004 Dec 1;39(11):1654-9 [15578367.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):322-31 [15667489.001]
  • [Cites] J Clin Microbiol. 2005 Feb;43(2):991-2 [15695726.001]
  • [Cites] Jpn J Infect Dis. 2005 Apr;58(2):70-2 [15858282.001]
  • [Cites] J Clin Microbiol. 2005 Jul;43(7):3110-3 [16000421.001]
  • [Cites] Jpn J Infect Dis. 2005 Dec;58(6):366-8 [16377869.001]
  • (PMID = 17093025.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; EC 3.5.2.6 / beta-Lactamases
  • [Other-IDs] NLM/ PMC1828969
  •  go-up   go-down


66. Jang HW, Park WK, Chang JC, Kim JW, Bae YK, Choi JH, Yun SS, Lee DS: [Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas]. Korean J Gastroenterol; 2006 Nov;48(5):355-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Undifferentiated carcinoma with osteoclast-like giant cells is a rare neoplasm of exocrine pancreas.
  • One case accompanied multiple metastatic liver masses with subhepatic lymph node enlargement.
  • In one case, there were small foci of adenocarcinoma components in the periphery of the tumor.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17132925.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


67. Dydensborg AB, Herring E, Auclair J, Tremblay E, Beaulieu JF: Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol Gastrointest Liver Physiol; 2006 May;290(5):G1067-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / genetics. Colon / cytology. Colonic Neoplasms / genetics. Epithelial Cells / metabolism. Intestines / cytology. Reverse Transcriptase Polymerase Chain Reaction


68. Zhang F, Xing L, Yu Y, Ma Y, Zou B: [Clinical Observation of Erlotnib in the Treatment of Non-small Cell Lung Cancer with Multimetastases in Elderly Patients.]. Zhongguo Fei Ai Za Zhi; 2009 Dec 20;12(12):1242-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the pathology, compared with the patients with squamous cell carcinoma, those with adenocarcinoma had not significant longer median overall (13.592+/-1.914 months vs 9.846+/-1.598 months, P=0.301) and progression-free survival times (7.367+/-0.923 months vs 6.615+/-1.366 months, P=0.488), The median survival was sigificantly related with meningeal metastasis, metastasis of liver, pleural efusion using survival analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723377.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


69. Liu CM, Zhu RL, Liu RH, Li HL, Shan L, Xu XK, Zhang WD: cis-Clerodane diterpenoids from the liverwort Gottschelia schizopleura and their cytotoxic activity. Planta Med; 2009 Dec;75(15):1597-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxic activities of compounds 1- 5 were evaluated against liver hepatoblastoma (HEP-G2), lung carcinoma (A549), breast ductal carcinoma (MDA-MB-435), and colon adenocarcinoma (LOVO) cell lines.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart. New York.
  • (PMID = 19579183.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Diterpenes; 0 / Diterpenes, Clerodane; 0 / Plant Extracts
  •  go-up   go-down


70. Ren JQ, Zhou ZW, Wan DS, Lu ZH, Chen G, Wang GQ, Tang SX, Wang JJ: [Univariate and multivariate regression analyses of recurrence and metastasis of colon cancer after radical resection]. Ai Zheng; 2006 May;25(5):591-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The overall recurrence and metastasis rate was 19.74%, and the liver metastasis rate was 9.87%.
  • Univariate analysis showed that blood transfusion, disease duration, tumor size, tumor movement, histological differentiation, Dukesostage, and lymph node involvement were correlated to recurrence and metastasis of colon cancer after operation; blood transfusion, serum concentration of carcinoembryonic antigen (CEA), tumor movement, histological differentiation, Dukesostage, and lymph node involvement were correlated to liver metastasis.
  • Multivariate analysis showed that tumor movement, histological differentiation, and lymph node involvement were prognostic factors for recurrence and metastasis, while serum concentration of CEA, histological differentiation, and lymph node involvement were prognostic factors for liver metastasis.
  • Patients with high serum concentration of CEA, poor histological differentiation, and lymph node involvement have increased risk of liver metastasis.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Liver Neoplasms / secondary. Neoplasm Recurrence, Local
  • [MeSH-minor] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Blood Transfusion. Carcinoembryonic Antigen / blood. Colectomy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687080.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


71. Kang MH, Kim SN, Kim NK, Park YI, Kim YW, Ryu KW, Lee JH, Lee JS, Park SR: Clinical outcomes and prognostic factors of metastatic gastric carcinoma patients who experience gastrointestinal perforation during palliative chemotherapy. Ann Surg Oncol; 2010 Dec;17(12):3163-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Signet Ring Cell / drug therapy. Intestinal Perforation / chemically induced. Liver Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Palliative Care. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20585878.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


72. Malik Z, Eng C: The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer. Clin Adv Hematol Oncol; 2007 Jan;5(1 Suppl 1):4-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491584.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


73. Inui T, Asakawa A, Morita Y, Mizuno S, Natori T, Kawaguchi A, Murakami M, Hishikawa Y, Inui A: HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. J Intern Med; 2006 Nov;260(5):484-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Liver Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Antibodies, Monoclonal, Humanized. Fatal Outcome. Gene Amplification / genetics. Genes, erbB-2. Humans. Japan. Male. Neoplasm Proteins / metabolism. Receptor, ErbB-2 / metabolism. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040255.001).
  • [ISSN] 0954-6820
  • [Journal-full-title] Journal of internal medicine
  • [ISO-abbreviation] J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


74. Park JY, Lim MC, Lim SY, Bae JM, Yoo CW, Seo SS, Kang S, Park SY: Port-site and liver metastases after laparoscopic pelvic and para-aortic lymph node dissection for surgical staging of locally advanced cervical cancer. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):176-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Port-site and liver metastases after laparoscopic pelvic and para-aortic lymph node dissection for surgical staging of locally advanced cervical cancer.
  • Recently, we experienced a case of port-site and liver metastases after 75 cases of laparoscopic transperitoneal pelvic lymph node dissection (PLND) and para-aortic lymph node dissection (PALND) for surgical staging of locally advanced cervical cancer.
  • A 45-year-old-woman with stage IIB cervical adenocarcinoma underwent laparoscopic PLND and PALND for surgical staging.
  • One month after the completion of therapy, both lateral and umbilical port-site and liver metastases were detected.
  • [MeSH-major] Adenocarcinoma / secondary. Laparoscopy. Liver Neoplasms / secondary. Lymph Nodes / surgery. Pelvis / surgery. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging


75. Stahl A, Stollfuss J, Ott K, Wieder H, Fink U, Schwaiger M, Weber WA: FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding. Nuklearmedizin; 2005;44(6):249-55; quiz N55-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 4/9 patients PET was incorrect (3 false positive due to suspicion of M1-lymph nodes or lung metastases, 1 false negative in disseminated liver metastases).
  • The patient with disseminated liver disease remained the single false negative.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / radionuclide imaging. Esophageal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Biopsy. Follow-Up Studies. Humans. Image Processing, Computer-Assisted. Neoplasm Staging. Reproducibility of Results. Survival Analysis. Time Factors. Tissue Distribution

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400385.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


76. Osada T, Hsu D, Hammond S, Hobeika A, Devi G, Clay TM, Lyerly HK, Morse MA: Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer; 2010 Jan 5;102(1):124-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.
  • BACKGROUND: Novel technologies to redirect T-cell killing against cancer cells are emerging.
  • We hypothesised that metastatic human colorectal cancer (CRC) previously treated with conventional chemotherapy would be sensitive to T-cell killing mediated by carcinoembryonic antigen (CEA)/CD3-bispecific T-cell-engaging BiTE antibody (MEDI-565).
  • METHODS: We analysed proliferation and lysis of CEA-positive (CEA+) CRC specimens that had survived previous systemic chemotherapy and biologic therapy to determine whether they could be killed by patient T cells engaged by MEDI-565 in vitro.
  • RESULTS: At low concentrations (0.1-1 ng ml(-1)), MEDI-565+ T cells caused reduced proliferation and enhanced apoptosis of CEA+ human CRC specimens.
  • High levels of soluble CEA did not impair killing by redirected T cells and there was no increase in resistance to T-cell killing despite multiple rounds of exposure.
  • CONCLUSIONS: This study shows for the first time that metastatic CRC specimens derived from patients previously treated with conventional chemotherapy can be lysed by patient T cells.
  • Clinical testing of cancer immunotherapies, such as MEDI-565 that result in exposure of tumours to large numbers of T cells, is warranted.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3927-35 [17440108.001]
  • [Cites] Annu Rev Immunol. 2007;25:243-65 [17129181.001]
  • [Cites] J Immunother. 2007 Nov-Dec;30(8):798-807 [18049331.001]
  • [Cites] Science. 2008 Aug 15;321(5891):974-7 [18703743.001]
  • [Cites] J Immunother. 2009 May;32(4):341-52 [19342971.001]
  • [Cites] Breast Cancer Res Treat. 2009 Oct;117(3):471-81 [18819003.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1711-9 [10815889.001]
  • [Cites] J Immunol. 2003 Apr 15;170(8):4397-402 [12682277.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1746-51 [12721250.001]
  • [Cites] Cancer Immun. 2001 Nov 12;1:10 [12747771.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):332-42 [12843795.001]
  • [Cites] Cancer Immunol Immunother. 2004 Jul;53(7):625-32 [15175907.001]
  • [Cites] Int J Cancer. 1994 Apr 1;57(1):67-72 [8150543.001]
  • [Cites] Int Immunol. 1996 Jan;8(1):57-63 [8671589.001]
  • [Cites] Semin Cancer Biol. 1999 Apr;9(2):67-81 [10202129.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):8426-34 [15576364.001]
  • [Cites] Int J Cancer. 2005 May 20;115(1):98-104 [15688411.001]
  • [Cites] Cancer Invest. 2005;23(4):338-51 [16100946.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1675-82 [16030029.001]
  • [Cites] Drug Discov Today. 2005 Sep 15;10(18):1237-44 [16213416.001]
  • [Cites] Mol Immunol. 2006 Feb;43(6):763-71 [16360021.001]
  • [Cites] Mol Immunol. 2006 Mar;43(8):1129-43 [16139892.001]
  • [Cites] Cancer Immunol Immunother. 2006 May;55(5):503-14 [16032400.001]
  • [Cites] Nat Rev Immunol. 2006 Dec;6(12):940-52 [17124515.001]
  • [Cites] Cancer Immunol Immunother. 2007 Oct;56(10):1551-63 [17310380.001]
  • (PMID = 19953093.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA100639; United States / NCI NIH HHS / CA / P01 CA078673; United States / NCI NIH HHS / CA / 5K12CA100639-05; United States / NCI NIH HHS / CA / P01 - 5 P01 CA078673
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antigens, CD3; 0 / Antigens, CD95; 0 / Carcinoembryonic Antigen; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; EC 3.4.21.- / Granzymes
  • [Other-IDs] NLM/ PMC2813763
  •  go-up   go-down


77. Park JJ, Lee YC, Kim BK, Kim JH, Park JC, Kim YJ, Lee SK, Song SY, Chung JB: Long-term clinical outcomes of self-expanding metal stents for treatment of malignant gastroesophageal junction obstructions and prognostic factors for stent patency: effects of anticancer treatments. Dig Liver Dis; 2010 Jun;42(6):436-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term clinical outcomes of self-expanding metal stents for treatment of malignant gastroesophageal junction obstructions and prognostic factors for stent patency: effects of anticancer treatments.
  • BACKGROUND: Self-expanding metal stent has emerged as an effective treatment option for malignant gastroesophageal junction obstruction.
  • AIM: To investigate the long-term clinical outcomes and prognostic factors, including treatment modalities, affecting stent patency in patients with malignant gastroesophageal junction obstruction given self-expanding metal stent insertions.
  • METHODS: A total 89 patients who underwent self-expanding metal stent insertion for malignant gastroesophageal junction obstruction were enrolled.
  • CONCLUSIONS: Self-expanding metal stent is a feasible and effective treatment for malignant gastroesophageal junction obstruction.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Endoscopy, Gastrointestinal. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Prosthesis Design. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19767253.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


78. Cummings LC, Payes JD, Cooper GS: Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer; 2007 Feb 15;109(4):718-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after hepatic resection in metastatic colorectal cancer: a population-based study.
  • BACKGROUND: Hepatectomy is the standard of care for patients with colorectal cancer who have isolated hepatic metastases; however, the long-term survival benefits of hepatectomy in this population have not been characterized well outside of case series.
  • For the current study, a population-based database was used to compare the survival of patients with liver metastases from colorectal cancer who did and did not undergo hepatectomy.
  • Liver metastasis diagnoses, colorectal resections, and hepatectomies were identified from hospital, outpatient, and physician-supplier claims.
  • Five-year survival from the time of cancer diagnosis was determined by the Kaplan-Meier method.
  • RESULTS: Among 13,599 patients who were identified with incident colorectal cancer and liver metastases, 7673 patients (56.4%) presented with stage IV disease, and the remaining patients presented with earlier stage disease and developed subsequent metastases.
  • Only 833 patients (6.1%) in the cohort underwent hepatic resection, and their 30-day mortality rate was 4.3%.
  • The 5-year survival was 32.8% among patients who underwent hepatic resection, compared with 10.5% among patients who did not undergo hepatic resection (P < .0001), and better survival was observed in the subset of patients who presented initially with disease in stages I through III.
  • In a Cox model, which was controlled for age, sex, race, comorbidities, and stage at presentation, lack of hepatic resection was associated with a 2.78-fold increased risk of death.
  • CONCLUSIONS: Although hepatectomy rates among patients with colorectal cancer were low, hepatic resection was associated with improved survival.
  • [MeSH-major] Adenocarcinoma / mortality. Colorectal Neoplasms / mortality. Hepatectomy / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Aged. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Registries. SEER Program. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17238180.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K05-CA90677; United States / NIDDK NIH HHS / DK / T32-DK61917
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH: Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int; 2008 Feb;58(2):104-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CIMP-high, microsatellite-stable (MSS) CRC were significantly associated with proximal location and nodal metastasis and had close but non-significant associations with liver metastasis.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. CpG Islands / genetics. DNA Methylation. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. ras Proteins / genetics
  • [MeSH-minor] DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Gene Expression Regulation, Neoplastic / genetics. Genomic Instability. Humans. Male. Microsatellite Repeats. Middle Aged. Mutation. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199160.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


80. Erkan M, Reiser-Erkan C, Michalski CW, Deucker S, Sauliunaite D, Streit S, Esposito I, Friess H, Kleeff J: Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia; 2009 May;11(5):497-508
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4264-6 [8797602.001]
  • [Cites] Gut. 1999 Apr;44(4):534-41 [10075961.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1041-56 [10353737.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):89-93 [15545970.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):907-21 [15825074.001]
  • [Cites] Histopathology. 2005 Jun;46(6):668-76 [15910598.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4421-32 [15856026.001]
  • [Cites] Mol Biol Cell. 2005 Aug;16(8):3488-500 [15901832.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):512-9 [17227797.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):218-27 [17224648.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1447-64 [17408641.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):1942-53 [17525262.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5076-82 [17545583.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):137 [17585412.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12890-5 [17652168.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):918-26 [18245495.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2085-93 [18381413.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Oct;295(4):G709-17 [18669622.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Oct;6(10):1155-61 [18639493.001]
  • [Cites] Cancer Biol Ther. 2008 Sep;7(9):1352-9 [18708761.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):242-8 [11001067.001]
  • [Cites] FEBS Lett. 2000 Dec 15;486(3):247-51 [11119712.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):519-27 [11923608.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3992-4003 [15082792.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):329-39 [15093540.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Am Rev Respir Dis. 1989 Oct;140(4):1104-7 [2478057.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] Cancer Res. 1991 Nov 15;51(22):6180-4 [1718597.001]
  • [Cites] Cell. 1998 Sep 18;94(6):715-25 [9753319.001]
  • (PMID = 19412434.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD31; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human
  • [Other-IDs] NLM/ PMC2671860
  •  go-up   go-down


81. Johnson JA, Everett BM, Katz JT, Loscalzo J: Clinical problem-solving. Painful purple toes. N Engl J Med; 2010 Jan 7;362(1):67-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Foot Diseases / etiology. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology. Thromboembolism / etiology
  • [MeSH-minor] Brain / pathology. Diagnosis, Differential. Echocardiography, Transesophageal. Endocarditis / etiology. Fatal Outcome. Fingers / blood supply. Humans. Infarction / etiology. Ischemia / etiology. Liver / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Toes / blood supply. Vision Disorders / etiology. Weight Loss


82. Li CC, Yang CR, Yu CC, Chen CS, Cheng CL, Ou YC, Ho HC, Hung SW, Li JR: Hepatic failure-induced hypogonadism in a prostate cancer patient. J Chin Med Assoc; 2010 Jul;73(7):389-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic failure-induced hypogonadism in a prostate cancer patient.
  • Here, we present a patient with metastatic prostate cancer to the pericardium who had low serum testosterone level due to hepatic failure.
  • Cytology revealed adenocarcinoma.
  • Perioperative intra-abdominal inflammatory process caused subsequent cholestasis and hepatic dysfunction.
  • The patient died due to hepatic failure in the 12(th) postoperative week.
  • [MeSH-major] Hypogonadism / etiology. Liver Failure / complications. Prostatic Neoplasms / complications

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20688306.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


83. Sagawa T, Sato Y, Abe S, Okuda T, Araki N, Takahari D, Okamoto T, Takayama T, Kato J, Niitsu Y: [Anaphylactic reaction to oxaliplatin--a case of colon cancer]. Gan To Kagaku Ryoho; 2006 Dec;33(13):2093-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After eight cycles of FOLFIRI regimen, lung and liver metastases showed progressive disease for response assessment by RECIST criteria.
  • [MeSH-major] Adenocarcinoma / drug therapy. Anaphylaxis / chemically induced. Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Organoplatinum Compounds / adverse effects

  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197761.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


84. Gutierrez G, Daniels IR, Garcia A, Ramia JM: Peritoneal carcinomatosis from a small bowel carcinoid tumour. World J Surg Oncol; 2006;4:75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The natural history is different from gastrointestinal adenocarcinoma, although its capacity to invade regional lymph nodes and generate distal metastasis can make the management more complex.
  • Over the next ten years, further surgery was required for disseminated disease with peritoneal carcinomatosis and liver metastasis.

  • Andalusian Health Repository. Full Text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2004 May;187(5):575-9 [15135668.001]
  • [Cites] J Pathol. 2000 Jan;190(1):76-9 [10640995.001]
  • [Cites] Br J Surg. 2003 Jun;90(6):687-93 [12808615.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):811-7 [12766586.001]
  • [Cites] Cancer. 1975 Aug;36(2):560-9 [1157019.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1086-93 [9070484.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):858-68 [10080850.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):813-29 [9024720.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1686-92 [8859181.001]
  • [Cites] World J Surg. 1996 Feb;20(2):203-7 [8661818.001]
  • [Cites] World J Surg. 1996 Feb;20(2):183-8 [8661815.001]
  • [Cites] World J Surg. 1996 Feb;20(2):142-6 [8661809.001]
  • [Cites] World J Surg. 1996 Feb;20(2):132-41 [8661808.001]
  • [Cites] World J Surg. 1996 Feb;20(2):126-31 [8661807.001]
  • [Cites] Curr Opin Oncol. 2006 Jan;18(1):9-15 [16357558.001]
  • [Cites] Ann Surg. 2005 May;241(5):776-83; discussion 783-5 [15849513.001]
  • [Cites] Surgery. 2005 Apr;137(4):411-6 [15800487.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2005 Jun;19(2):265-76 [15763700.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):117-22 [15213627.001]
  • [Cites] Acta Oncol. 2003;42(7):672-92 [14690153.001]
  • (PMID = 17083717.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1635417
  •  go-up   go-down


85. Watanabe M, Tsuchiya M, Takita W, Otsuka Y, Tamura A, Yamazaki K, Koshino H, Kurihara A, Kaneko H, Teramoto T: [Case report of a liver metastasis from rectal cancer achieving complete response (CR) by a combination of intra-hepatic arterial infusion of irinotecan (CPT-11) with degradable starch microspheres (DSM) and weekly high-dose intra-hepatic arterial chemotherapy with 5-FU]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1485-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report of a liver metastasis from rectal cancer achieving complete response (CR) by a combination of intra-hepatic arterial infusion of irinotecan (CPT-11) with degradable starch microspheres (DSM) and weekly high-dose intra-hepatic arterial chemotherapy with 5-FU].
  • A 67-year-old woman, who was diagnosed with rectal cancer and liver metastasis, underwent a low anterior resection of the rectum in May 2004.
  • Two months later, the level of tumor markers increased and a CT scan revealed a 45 x 35 mm liver metastasis in the S(8) segment.
  • She was referred to our hospital for treatment of the liver tumor.
  • Intra-hepatic arterial infusion of irinotecan (CPT-11) and mitomycin C (MMC) with degradable starch microspheres (DSM) was given in July 2004.
  • Following this, a 34-week course of weekly high-dose intra-hepatic arterial 5-FU infusion (5-FU 1,000 mg/m(2)) was performed.
  • In April 2005, the size of the liver metastasis decreased, and the level of serum tumor marker normalized.
  • This case suggests that the use of intra-hepatic arterial infusion of CPT-11 and MMC with DSM is useful for the treatment of liver metastases in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusion Pumps, Implantable. Infusions, Intra-Arterial. Mitomycin / administration & dosage. Starch / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033243.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / degradable starch microspheres; 50SG953SK6 / Mitomycin; 7673326042 / irinotecan; 9005-25-8 / Starch; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


86. Ricci F, Kern SE, Hruban RH, Iacobuzio-Donahue CA: Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype. Cancer Biol Ther; 2005 Mar;4(3):302-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using nonradioactive in situ hybridization, we evaluated the gene expression patterns of three genes previously shown to be robust markers of the juxtatumoral stroma within eight infiltrating ductal adenocarcinoma of the pancreas (ApoC1, ApoD and MMP11), and compared these patterns to those associated with seven infiltrating colloid and tubular carcinomas arising in association with intraductal papillary mucinous neoplasms (IPMNs), a histologically distinct form of primary carcinoma of the pancreas, two surgically resected samples of chronic pancreatitis and two surgically resected pancreatic cancer liver metastases.
  • Robust juxtatumoral stromal expression was noted for all three markers within all eight conventional infiltrating ductal adenocarcinoma tissues, but not in samples of chronic pancreatitis.
  • This observation was further supported by two infiltrating carcinomas arising in an IPMN that showed both tubular and colloid growth patterns within the same neoplasm indicating the host stromal response observed may relate to infiltrative growth pattern rather than the biology of the primary tumor type.
  • Moreover, these robust patterns within conventional infiltrating ductal adenocarcinomas were not retained within matched metastases to the liver, indicating the importance of the tumor microenvironment in the host stromal response.
  • [MeSH-minor] Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / secondary. Apolipoprotein C-I. Apolipoproteins / analysis. Apolipoproteins / genetics. Apolipoproteins C / analysis. Apolipoproteins C / genetics. Apolipoproteins D. Carcinoma, Pancreatic Ductal / chemistry. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / secondary. Cell Communication / genetics. Gene Expression. Glycoproteins / analysis. Glycoproteins / genetics. Humans. In Situ Hybridization. Liver Neoplasms / chemistry. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Matrix Metalloproteinase 11. Membrane Transport Proteins / analysis. Membrane Transport Proteins / genetics. Metalloendopeptidases / analysis. Metalloendopeptidases / genetics. RNA, Messenger / analysis. RNA, Messenger / metabolism. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876873.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA1066110; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APOD protein, human; 0 / Apolipoprotein C-I; 0 / Apolipoproteins; 0 / Apolipoproteins C; 0 / Apolipoproteins D; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Membrane Transport Proteins; 0 / RNA, Messenger; EC 3.4.24.- / Matrix Metalloproteinase 11; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


87. McCoy AM, Hackett ES, Callan RJ, Powers BE: Alimentary-associated carcinomas in five Vietnamese potbellied pigs. J Am Vet Med Assoc; 2009 Dec 1;235(11):1336-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Types of tumor included cholangiocellular carcinoma, transmural gastric carcinoma, small intestinal adenocarcinoma, metastatic hepatocellular carcinoma, and carcinoma.
  • The tumors involved the stomach, small intestine, spiral colon, liver, and gall bladder.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951106.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Yeo SG, Kim DY, Kim TH, Kim SY, Hong YS, Jung KH: Whole-liver radiotherapy for end-stage colorectal cancer patients with massive liver metastases and advanced hepatic dysfunction. Radiat Oncol; 2010;5:97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-liver radiotherapy for end-stage colorectal cancer patients with massive liver metastases and advanced hepatic dysfunction.
  • BACKGROUND: To investigate whether whole-liver radiotherapy (RT) is beneficial in end-stage colorectal cancer with massive liver metastases and severe hepatic dysfunction.
  • METHODS: Between June 2004 and July 2008, 10 colorectal cancer patients, who exhibited a replacement of over three quarters of their normal liver by metastatic tumors and were of Child-Pugh class B or C in liver function with progressive disease after undergoing chemotherapy, underwent whole-liver RT.
  • Improvement in liver function tests, defined as a decrease in the levels within 1 month after RT, symptom palliation, toxicity, and overall survival were analyzed retrospectively.
  • CONCLUSIONS: Although limited by small case number, this study demonstrated a possible role of whole-liver RT in improving hepatic dysfunction and delaying mortality from hepatic failure for end-stage colorectal cancer patients with massive liver metastases.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Colorectal Neoplasms / radiotherapy. Liver Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1442-5 [11896089.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1223-9 [2557307.001]
  • [Cites] Tumori. 2004 Jan-Feb;90(1):73-9 [15143976.001]
  • [Cites] J Pain Symptom Manage. 2004 Oct;28(4):351-5 [15471652.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):445-50 [7751185.001]
  • [Cites] J Pain Symptom Manage. 1995 Oct;10(7):548-55 [8537697.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):722-8 [8622017.001]
  • [Cites] Eur J Surg Oncol. 1999 Oct;25(5):451-63 [10527592.001]
  • [Cites] Semin Radiat Oncol. 2005 Oct;15(4):273-8 [16183481.001]
  • [Cites] Semin Radiat Oncol. 2005 Oct;15(4):284-98 [16183483.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1395-403 [16505413.001]
  • [Cites] Am J Clin Oncol. 2006 Dec;29(6):562-7 [17148992.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):793-8 [17197128.001]
  • [Cites] Surg Oncol. 2007 Jul;16(1):33-45 [17544654.001]
  • [Cites] Eur J Surg Oncol. 2007 Oct;33(8):1003-9 [17350218.001]
  • [Cites] Langenbecks Arch Surg. 2008 Jan;393(1):13-9 [17909846.001]
  • [Cites] Surg Oncol. 2007 Dec;16(4):277-91 [17935975.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12):1606-12 [18071347.001]
  • [Cites] Cancer J. 2010 Mar-Apr;16(2):150-5 [20404612.001]
  • [Cites] Cancer. 2010 Jul 1;116(13):3251-6 [20564632.001]
  • [Cites] Jpn J Clin Oncol. 2003 Mar;33(3):132-5 [12672790.001]
  • (PMID = 20977728.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 3.1.3.1 / Alkaline Phosphatase; RFM9X3LJ49 / Bilirubin
  • [Other-IDs] NLM/ PMC2987942
  •  go-up   go-down


89. Menigatti M, Cattaneo E, Sabates-Bellver J, Ilinsky VV, Went P, Buffoli F, Marquez VE, Jiricny J, Marra G: The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis. Mol Cancer; 2009 Dec 16;8:124
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of the PTPRR-1 isoform was inactivated in colorectal cancer cells as a result of de novo CpG island methylation and enrichment of transcription-repressive histone-tail marks, mainly H3K27me3.
  • De novo methylation of the PTPRR-1 transcription start site was demonstrated in 29/36 (80%) colorectal adenomas, 42/44 (95%) colorectal adenocarcinomas, and 8/8 (100%) liver metastases associated with the latter tumors.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8430-8 [16951153.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46 [17057753.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):924-35 [17109012.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Gastroenterology. 2007 Feb;132(2):628-32 [17320548.001]
  • [Cites] J Neurochem. 2007 May;101(3):829-40 [17266727.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1050-63 [17437993.001]
  • [Cites] Nature. 2007 Nov 15;450(7168):415-9 [17928865.001]
  • [Cites] Mol Cancer Res. 2007 Dec;5(12):1263-75 [18171984.001]
  • [Cites] FEBS J. 2008 Mar;275(5):816-30 [18298790.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1148-59 [18337604.001]
  • [Cites] Oncogene. 2008 Jul 24;27(32):4503-8 [18391979.001]
  • [Cites] PLoS Genet. 2008;4(8):e1000145 [18670629.001]
  • [Cites] Oncogene. 2009 Feb 12;28(6):899-909 [19060925.001]
  • [Cites] Cell Death Differ. 2009 Mar;16(3):368-77 [18846109.001]
  • [Cites] Cerebellum. 2009 Jun;8(2):80-8 [19137382.001]
  • [Cites] Mol Cancer Ther. 2009 Jun;8(6):1579-88 [19509260.001]
  • [Cites] Cell. 1987 Sep 11;50(6):823-9 [3113737.001]
  • [Cites] Anat Rec. 2000 Mar 1;258(3):221-34 [10705342.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7164-9 [11416201.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29503-9 [12042304.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Genes Dev. 2002 Nov 15;16(22):2893-905 [12435631.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6390-4 [12438221.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1941-8 [12454851.001]
  • [Cites] Science. 2003 Apr 4;300(5616):131-5 [12649488.001]
  • [Cites] Biochem J. 2003 May 15;372(Pt 1):193-201 [12583813.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Oncogene. 2003 Sep 25;22(41):6319-31 [14508512.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Science. 2004 May 21;304(5674):1164-6 [15155950.001]
  • [Cites] Cell. 2004 Jun 11;117(6):699-711 [15186772.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1592-605 [15231737.001]
  • [Cites] Nat Genet. 1998 Jun;19(2):187-91 [9620779.001]
  • [Cites] Nature. 1998 May 28;393(6683):386-9 [9620804.001]
  • [Cites] EMBO J. 1998 Dec 15;17(24):7337-50 [9857190.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):813-22 [9989833.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Mar 5;256(1):52-6 [10066421.001]
  • [Cites] Am J Physiol. 1999 Sep;277(3 Pt 1):G631-41 [10484389.001]
  • [Cites] J Hum Genet. 2005;50(4):159-67 [15824892.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):307-20 [16557282.001]
  • [Cites] Biochem J. 2006 May 1;395(3):483-91 [16441242.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1096-109 [17030180.001]
  • (PMID = 20015382.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.1.3.48 / PTPRR protein, human; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 7
  • [Other-IDs] NLM/ PMC2801661
  •  go-up   go-down


90. Futagami S, Tatsuguchi A, Hiratsuka T, Shindo T, Horie A, Hamamoto T, Ueki N, Kusunoki M, Miyake K, Gudis K, Tsukui T, Sakamoto C: Monocyte chemoattractant protein 1 and CD40 ligation have a synergistic effect on vascular endothelial growth factor production through cyclooxygenase 2 upregulation in gastric cancer. J Gastroenterol; 2008;43(3):216-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Female. Gastritis / microbiology. Gastritis / pathology. Humans. Immunohistochemistry. Lymphatic Metastasis. Macrophages / metabolism. Male. Mesoderm / cytology. Mesoderm / pathology. Middle Aged. Polymerase Chain Reaction. RNA, Messenger / metabolism. Receptors, CCR2 / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 1997 Dec 27;64(12):1765-74 [9422418.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40 [9096394.001]
  • [Cites] Gut. 2004 Jul;53(7):1035-43 [15194658.001]
  • [Cites] J Immunol. 1998 Feb 1;160(3):1053-7 [9570516.001]
  • [Cites] Virchows Arch. 2002 Jun;440(6):583-8 [12070596.001]
  • [Cites] Gut. 2006 Jan;55(1):54-61 [16085694.001]
  • [Cites] Blood. 2000 Jul 1;96(1):34-40 [10891427.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7629-36 [16278381.001]
  • [Cites] Pharm Res. 1995 Nov;12(11):1598-604 [8592656.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4625-9 [8840975.001]
  • [Cites] Gut. 2003 Sep;52(9):1257-64 [12912855.001]
  • [Cites] J Clin Invest. 2005 Nov;115(11):2979-91 [16239969.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G444-51 [15246970.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):4079-83 [14666722.001]
  • [Cites] Pathol Res Pract. 1998;194(5):335-40 [9651946.001]
  • [Cites] Atherosclerosis. 2002 Jul;163(1):9-16 [12048117.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):42-9 [11172294.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1147-51 [11948126.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3801-8 [11090063.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1667-74 [15330899.001]
  • [Cites] J Immunol. 2004 Feb 15;172(4):2147-54 [14764680.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):387-97 [9024292.001]
  • [Cites] Lab Invest. 1997 Apr;76(4):579-90 [9111518.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Aug;293(2):R651-61 [17522124.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):220-4 [12397639.001]
  • [Cites] Gut. 2003 Oct;52(10):1435-41 [12970136.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1592-8 [10197634.001]
  • [Cites] World J Gastroenterol. 2006 Dec 21;12(47):7598-603 [17171787.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):488-95 [15116331.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):773-8 [12632067.001]
  • (PMID = 18373164.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CCR2 protein, human; 0 / Chemokine CCL2; 0 / RNA, Messenger; 0 / Receptors, CCR2; 0 / Vascular Endothelial Growth Factor A; 147205-72-9 / CD40 Ligand; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


91. Quinn AE, Pinkney M, Piggott NH, Calvert H, Milton ID, Lunec J: A monoclonal antibody for detection of folylpolyglutamate synthetase in paraffin embedded tissues. Hybridoma (Larchmt); 2009 Dec;28(6):415-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical analysis of FPGS using hybridoma clone NN3.2 in a panel of normal tissues demonstrated wide expression including strong immunoreactivity in the brush border and crypts of colon, liver hepatocytes, and lymphoid cells.
  • Analysis of a panel of malignant and benign tissues demonstrated wide expression with variable intensities of staining and patterns of cytoplasmic reactivity.
  • Stronger staining was observed in malignant tissue compared with that of normal adjacent tissue, particularly in ovarian and colon adenocarcinoma cases.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20025500.001).
  • [ISSN] 1557-8348
  • [Journal-full-title] Hybridoma (2005)
  • [ISO-abbreviation] Hybridoma (Larchmt)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / DNA Primers; 0 / Recombinant Fusion Proteins; EC 6.3.2.- / Peptide Synthases; EC 6.3.2.17 / folylpolyglutamate synthetase
  •  go-up   go-down


92. Pereira ME, Viner TC: Oviduct adenocarcinoma in some species of captive snakes. Vet Pathol; 2008 Sep;45(5):693-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oviduct adenocarcinoma in some species of captive snakes.
  • This article reports 5 cases of oviduct adenocarcinoma in adult captive snakes from Smithsonian's National Zoological Park.
  • This neoplasm was found in 1 of each of the following species: emerald tree boa (Corallus caninus), Amazonian tree boa (Corallus enydris enydris), Burmese rock python (Python molurus bivittatus), Northern pine snake (Pituophis melanoleucus melanoleucus), and corn snake (Elaphe guttata).
  • Solid metastases were seen in all animals except the Northern pine snake and involved several organs including the liver, lung, and heart.
  • [MeSH-major] Adenocarcinoma / veterinary. Animals, Zoo. Genital Neoplasms, Female / veterinary. Oviducts / pathology. Snakes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18725476.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. H Salim OE, Hamid HK, Mekki SO, Suleiman SH, Ibrahim SZ: Colorectal carcinoma associated with schistosomiasis: a possible causal relationship. World J Surg Oncol; 2010;8:68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Mucinous / parasitology. Colorectal Neoplasms / parasitology. Schistosoma mansoni / pathogenicity. Schistosomiasis mansoni / parasitology. Sigmoid Neoplasms / parasitology

  • Genetic Alliance. consumer health - Schistosomiasis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Oncol. 2005;27(4):245-53 [16308474.001]
  • [Cites] Int J Immunopathol Pharmacol. 2005 Jul-Sep;18(3):503-11 [16164831.001]
  • [Cites] Contrib Microbiol. 2006;13:81-100 [16627960.001]
  • [Cites] Lancet. 2006 Sep 23;368(9541):1106-18 [16997665.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):175-81 [16786317.001]
  • [Cites] Immunobiology. 2007;212(6):475-90 [17544832.001]
  • [Cites] Adv Parasitol. 2007;65:239-96 [18063098.001]
  • [Cites] Int J Biol Markers. 2005 Oct-Dec;20(4):197-203 [16398400.001]
  • [Cites] Jpn J Clin Oncol. 1999 Nov;29(11):576-81 [10678562.001]
  • [Cites] West Afr J Med. 2000 Oct-Dec;19(4):273-6 [11391839.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1037-46 [11592777.001]
  • [Cites] N Engl J Med. 2002 Apr 18;346(16):1212-20 [11961151.001]
  • [Cites] J Helminthol. 2004 Mar;78(1):47-50 [14972036.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17 [15194558.001]
  • [Cites] Environ Mol Mutagen. 2004;44(1):3-9 [15199542.001]
  • [Cites] Chin Med J. 1965 Aug;84(8):513-25 [5865022.001]
  • [Cites] Dis Colon Rectum. 1976 Jul-Aug;19(5):460-9 [939164.001]
  • [Cites] Am J Trop Med Hyg. 1978 Jan;27(1 Pt 1):55-75 [626283.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1661-75 [7417960.001]
  • [Cites] Lancet. 1981 May 2;1(8227):971-3 [6112388.001]
  • [Cites] J R Soc Med. 1981 Sep;74(9):645 [7288806.001]
  • [Cites] Int J Cancer. 1984 Sep 15;34(3):315-8 [6480152.001]
  • [Cites] Ann Acad Med Singapore. 1984 Apr;13(2):142-8 [6497313.001]
  • [Cites] J Infect Dis. 1985 Oct;152(4):722-6 [2864378.001]
  • [Cites] Mutat Res. 1989 Oct;224(2):229-33 [2552310.001]
  • [Cites] Gut. 1990 Apr;31(4):439-42 [2110925.001]
  • [Cites] Chin Med J (Engl). 1991 Jan;104(1):64-70 [1908760.001]
  • [Cites] Am J Gastroenterol. 1991 Sep;86(9):1283-4 [1909088.001]
  • [Cites] Trop Gastroenterol. 1991 Oct-Dec;12(4):180-4 [1667558.001]
  • [Cites] Nutr Cancer. 1993;20(1):13-20 [8415126.001]
  • [Cites] Mem Inst Oswaldo Cruz. 1992;87 Suppl 4:291-6 [1343911.001]
  • [Cites] Mutat Res. 1994 Mar 1;305(2):273-81 [7510038.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1929s-1933s [8137314.001]
  • [Cites] Histol Histopathol. 1998 Oct;13(4):961-6 [9810489.001]
  • [Cites] Cancer Lett. 1998 Sep 25;131(2):215-21 [9851256.001]
  • [Cites] Ann Trop Med Parasitol. 2005 Jan;99(1):47-52 [15701255.001]
  • [Cites] Parasitol Int. 2005 Mar;54(1):29-34 [15710547.001]
  • [Cites] FEMS Microbiol Lett. 2005 Mar 1;244(1):1-7 [15727814.001]
  • [Cites] Environ Mol Mutagen. 2005 Mar-Apr;45(2-3):284-303 [15744742.001]
  • (PMID = 20704754.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2928231
  •  go-up   go-down


94. Kubisch CH, Beigel F, Ihrler S, Goke B, Reiser MF, Hoffmann RT: Oesophageal ulceration after selective internal radiation therapy in a patient with carcinoma of unknown primary. Z Gastroenterol; 2010 May;48(5):546-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with solely liver metastases from adenocarinomas represent the most frequent subgroup with an unfavourable prognosis.
  • CASE: We present a patient with hepatic CUP.
  • After cycles of chemotherapy and hemihepatectomy the tumor returned and showed hepatic progression.
  • Three years after diagnosis she is still alive and tumorfree.
  • CONCLUSIONS: SIRT is a new, effective treatment in patients with hepatic CUP.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Brachytherapy / adverse effects. Duodenal Ulcer / pathology. Embolization, Therapeutic. Esophageal Diseases / pathology. Esophagus / radiation effects. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / radiotherapy. Radiation Injuries / pathology. Stomach Ulcer / pathology. Ulcer / pathology

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449787.001).
  • [ISSN] 1439-7803
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


95. Kaira K, Tsuchiya S, Sunaga N, Yanagitani N, Watanabe S, Imai H, Hisada T, Ishizuka T, Saito R, Mori M: A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer. Am J Clin Oncol; 2007 Feb;30(1):51-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB and IV NSCLC, >70 years of age, performance status (ECOG) 0-2, with adequate bone marrow, renal, liver and cardiac function, were treated with docetaxel and carboplatin.
  • Nonhematologic toxicities were generally mild, and included grade 3 constipation in 1 patient (4%) and grade 3 renal disorder in 1 patient (4%).
  • [MeSH-minor] Adenocarcinoma / drug therapy. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Neoplasm Staging. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278895.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


96. Fukuhara T, Egashira A, Imamura M, Ikegami T, Oki E, Soejima Y, Sadanaga N, Taketomi A, Yao T, Morita M, Kakeji Y, Tsuneyoshi M, Maehara Y: Proctocolectomy for colon cancer associated with ulcerative colitis a few months after living donor liver transplantation for primary sclerosing cholangitis: report of a case. Surg Today; 2009;39(1):59-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proctocolectomy for colon cancer associated with ulcerative colitis a few months after living donor liver transplantation for primary sclerosing cholangitis: report of a case.
  • We report a case of CRC treated successfully by proctocolectomy 8 months after living donor liver transplantation (LDLT) for primary sclerosing cholangitis (PSC).
  • [MeSH-major] Adenocarcinoma / surgery. Cholangitis, Sclerosing / surgery. Colitis, Ulcerative / complications. Colonic Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Anastomosis, Surgical. Early Diagnosis. Humans. Living Donors. Male. Middle Aged. Risk Factors. Treatment Outcome


97. Banzo J, Prats E, Ubieto MA, Alonso V, Razola P, Tardín L, Andrés A, Santapau A: [Liver metastasis in a patient with adenocarcinoma of the colon and typical pulmonary carcinoid tumor]. Rev Esp Med Nucl; 2009 Sep-Oct;28(5):253-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver metastasis in a patient with adenocarcinoma of the colon and typical pulmonary carcinoid tumor].
  • [Transliterated title] Metástasis hepática en un paciente con adenocarcinoma de colon y tumor carcinoide pulmonar típico.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoid Tumor. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms. Neoplasms, Multiple Primary


98. Terada T: Hepatic multiple minute inflammatory pseudotumors containing many biliary elements and hepatolithiasis: a suggestion of biliary origin. Scand J Gastroenterol; 2010 May;45(5):633-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic multiple minute inflammatory pseudotumors containing many biliary elements and hepatolithiasis: a suggestion of biliary origin.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Lithiasis / diagnosis. Liver Diseases / diagnosis
  • [MeSH-minor] Adenocarcinoma / surgery. Bile Ducts, Intrahepatic / pathology. Colonic Neoplasms / surgery. Hepatectomy / methods. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20230183.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


99. Sadahiro S, Suzuki T, Maeda Y, Tanaka A, Ishikawa K, Makuuchi H, Murayama C: Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer. Oncology; 2009;76(5):338-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Aged, 80 and over. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Tegafur / administration & dosage. Treatment Outcome. Young Adult


100. Ozkan M, Akbudak IH, Deniz K, Dikilitas M, Dogu GG, Berk V, Karaca H, Er O, Altinbas M: Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. Asian Pac J Cancer Prev; 2010;11(1):181-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Female. Humans. Immunoenzyme Techniques. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / secondary. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593954.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement